LIFEPOINT HOSPITALS, INC. Form 10-Q April 29, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR

x = 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2011

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR

o 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-51251

LifePoint Hospitals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware 20-1538254
(State or Other Jurisdiction of Incorporation or Organization) Identification No.)

103 Powell Court
Brentwood, Tennessee
(Address Of Principal Executive Offices)

(Zip Code)

(615) 372-8500

(Registrant s Telephone Number, Including Area Code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act:

Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of April 22, 2011, the number of outstanding shares of the registrant s Common Stock was 52,490,814.

Not Applicable 2

Not Applicable 3

LifePoint Hospitals, Inc.

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION Item 1.	
Financial Statements	1
Item 2.	21
Management s Discussion and Analysis of Financial Condition and Results of Operations	<u>21</u>
Item 3.	<u>38</u>
Quantitative and Qualitative Disclosures about Market Risk Item 4.	
Controls and Procedures	<u>39</u>
PART II OTHER INFORMATION	
Item 1.	<u>40</u>
<u>Legal Proceedings</u> <u>Item 1A.</u>	
Risk Factors	<u>40</u>
Item 2.	<u>40</u>
<u>Unregistered Sales of Equity Securities and Use of Proceeds</u> <u>Item 6.</u>	
	<u>42</u>
<u>Exhibits</u>	

PART I FINANCIAL INFORMATION

Item 1. Financial Statements.

LIFEPOINT HOSPITALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Unaudited (In millions, except per share amounts)

	Three Mo	onths
	Ended	
	March 31	,
	2011	2010
Revenues	\$888.6	\$786.2
Salaries and benefits	334.4	303.3
Supplies	118.7	108.4
Other operating expenses	161.6	140.4
Provision for doubtful accounts	130.1	102.1
Depreciation and amortization	39.7	36.1
Interest expense, net	29.2	25.1
	813.7	715.4
Income from continuing operations before income taxes	74.9	70.8
Provision for income taxes	28.4	26.6
Income from continuing operations	46.5	44.2
Income (loss) from discontinued operations, net of income taxes	0.3	(0.4)
Net income	46.8	43.8
Less: Net income attributable to noncontrolling interests	(0.7)	(0.9)
Net income attributable to LifePoint Hospitals, Inc.	\$46.1	\$42.9
Basic earnings (loss) per share attributable to LifePoint Hospitals, Inc. stockholders:		
Continuing operations	\$0.91	\$0.82
Discontinued operations	0.01	(0.01)
Net income	\$0.92	\$0.81
Diluted earnings (loss) per share attributable to LifePoint Hospitals, Inc.		
stockholders:		
Continuing operations	\$0.89	\$0.80
Discontinued operations		(0.01)
Net income	\$0.89	\$0.79
Weighted average shares and dilutive securities outstanding:		
Basic	50.2	53.2

Diluted	51.6	54.5	
Amounts attributable to LifePoint Hospitals, Inc. stockholders:			
Income from continuing operations, net of income taxes	\$45.8	\$43.3	
Income (loss) from discontinued operations, net of income taxes	0.3	(0.4)
Net income	\$46.1	\$42.9	

LIFEPOINT HOSPITALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in millions, except per share amounts)

ASSETS	March 31, 2011 (Unaudited)	December 31, 2010 ^(a)
Current assets:		
Cash and cash equivalents	\$276.2	\$207.4
Accounts receivable, less allowances for doubtful accounts of \$487.5 and \$459.8 at March 31, 2011 and December 31, 2010, respectively	399.9	387.3
Inventories	84.1	84.6
Prepaid expenses	17.4	13.9
Income taxes receivable		5.5
Deferred tax assets	106.9	99.7
Other current assets	25.9	24.7
	910.4	823.1
Property and equipment:		
Land	86.6	85.9
Buildings and improvements	1,535.0	1,532.9
Equipment	972.9	950.2
Construction in progress (estimated cost to complete and equip after March 31,	62.3	39.4
2011 is \$144.5)	02.3	39.4
	2,656.8	2,608.4
Accumulated depreciation	(973.3)	(939.8)
	1,683.5	1,668.6
Deferred loan costs, net	25.7	27.2
Intangible assets, net	69.7	73.1
Other	17.6	20.2
Goodwill	1,551.2	1,550.7
Total assets	\$4,258.1	\$4,162.9
LIABILITIES AND EQUITY		
Current liabilities:		
Accounts payable	\$94.2	\$89.0
Accrued salaries	80.6	101.4
Accrued interest	25.7	16.0
Income taxes payable	25.5	
Other current liabilities	113.5	116.5
Current maturities of long-term debt	1.3	1.4
<u> </u>	340.8	324.3
Long-term debt	1,576.1	1,570.5

Deferred income tax liabilities	213.4	211.2
Reserves for self-insurance claims and other liabilities	132.5	131.8
Long-term income tax liability	19.4	18.5
Total liabilities	2,282.2	2,256.3
Redeemable noncontrolling interests	15.3	15.3
Equity:		
LifePoint Hospitals, Inc. stockholders equity:		
Preferred stock, \$0.01 par value; 10,000,000 shares authorized; no shares issued		
Common stock, \$0.01 par value; 90,000,000 shares authorized; 62,471,721 and		
61,450,098 shares issued at March 31, 2011 and December 31, 2010,	0.6	0.6
respectively		
Capital in excess of par value	1,315.9	1,289.4
Accumulated other comprehensive loss	(1.5)	(4.0)
Retained earnings	950.1	904.0
Common stock in treasury, at cost, 10,135,495 and 9,991,316 shares at March	(308.0)	(302.5)
31, 2011 and December 31, 2010, respectively	(308.0)	(302.3)
Total LifePoint Hospitals, Inc. stockholders equity	1,957.1	1,887.5
Noncontrolling interests	3.5	3.8
Total equity	1,960.6	1,891.3
Total liabilities and equity	\$4,258.1	\$4,162.9

Derived from audited consolidated financial statements.

(a)

LIFEPOINT HOSPITALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited (In millions)

	Three Months Ended March 31,			ded
	2011		2010	
Cash flows from operating activities:				
Net income	\$46.8		\$43.8	
Adjustments to reconcile net income to net cash provided by operating activities:				
(Income) loss from discontinued operations	(0.3))	0.4	
Stock-based compensation	5.7		5.8	
Depreciation and amortization	39.7		36.1	
Amortization of physician minimum revenue guarantees	4.6		3.9	
Amortization of convertible debt discounts	5.9		5.5	
Amortization of deferred loan costs	1.5		2.4	
Deferred income tax benefit	(2.7)	(4.1)
Reserve for self-insurance claims, net of payments	4.7		4.1	
Increase (decrease) in cash from operating assets and liabilities, net of effects from				
acquisitions and divestitures:				
Accounts receivable	(14.5)	(24.7)
Inventories and other current assets	(1.8)	(0.4))
Accounts payable and accrued expenses	(5.4)	(19.0)
Income taxes payable /receivable	31.0		29.6	
Other	0.6		0.1	
Net cash provided by operating activities-continuing operations	115.8		83.5	
Net cash provided by (used in) operating activities-discontinued operations	0.2		(0.2))
Net cash provided by operating activities	116.0)	83.3	
Cash flows from investing activities:				
Purchase of property and equipment	(55.9)	(34.0)
Acquisitions, net of cash acquired	(1.7)	(16.9)
Other	(0.9))		
Net cash used in investing activities	(58.5)	(50.9)
Cash flows from financing activities:				
Repurchases of common stock	(5.5)	(9.0)
Payment of debt financing costs			(4.4)
Proceeds from exercise of stock options	17.5		9.2	
Proceeds from employee stock purchase plans	0.7		0.6	
Distributions to noncontrolling interests, net of proceeds	(1.0)	(0.5))

Proceeds from redeemable noncontrolling interests		4.2
Capital lease payments and other	(0.4)	(0.3)
Net cash provided by (used in) financing activities	11.3	(0.2)
Change in cash and cash equivalents	68.8	32.2
Cash and cash equivalents at beginning of period	207.4	187.2
Cash and cash equivalents at end of period	\$276.2	\$219.4
Supplemental disclosure of cash flow information:		
Interest payments	\$11.9	\$13.3
Capitalized interest	\$0.3	\$0.1
Income taxes paid, net	\$0.3	\$1.1

LIFEPOINT HOSPITALS, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY For the Three Months Ended March 31, 2011 Unaudited (In millions)

	LifePoint Hospitals, Inc. Stockholders									
	Commo	on	Capital in Excess of Par Value	Compre		Treasur Stock	ry	Noncor Interest	ntrolling s	
	Shares	Amou	nt	(loss)					Total	
Balance at December 31, 2010 ^(a)	51.5	\$0.6	\$1,289.4	\$(4.0)	\$904.0	\$(302.	5)	\$3.8	\$1,891.	.3
Comprehensive income:										
Net income					46.1			0.7	46.8	
Net change in fair value of interest rate swap, net of tax provision of \$1.4				2.5					2.5	
Total comprehensive income									49.3	
Exercise of stock options and tax effects of stock-based awards	0.6		20.1						20.1	
Stock activity in connection with employee stock purchase plan			0.7						0.7	
Stock-based compensation	0.3		5.7						5.7	
Repurchases of common stock, at cost	(0.1)					(5.5)		(5.5)
Cash distributions to noncontrolling interests								(1.0)	(1.0)
Balance at March 31, 2011	52.3	\$0.6	\$1,315.9	\$(1.5)	\$950.1	\$(308.0	0)	\$3.5	\$1,960.	.6
(a)	Deriv	ed from	audited co	nsolidated	d financial	stateme	ents			

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 1. Organization, Basis of Presentation, and Adoption of New Accounting Standard

Organization

LifePoint Hospitals, Inc., a Delaware corporation, acting through its subsidiaries, operates general acute care hospitals in non-urban communities in the United States. Unless the context otherwise indicates, LifePoint Hospitals, Inc. and its subsidiaries are referred to herein as the Company. At March 31, 2011, on a consolidated basis, the Company operated 52 hospital campuses in 17 states. Unless noted otherwise, discussions in these notes pertain to the Company s continuing operations, which exclude the results of those facilities that have been previously disposed.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, and disclosures considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2011 are not necessarily indicative of the results that may be expected for the year ending December 31, 2011. For further information, refer to the consolidated financial statements and notes thereto included in the Company s Annual Report on Form 10-K for the year ended December 31, 2010.

Adoption of New Accounting Standard

Effective January 1, 2011 and retrospectively for all periods presented, the Company adopted the provisions of Accounting Standards Update (ASU) 2010-24, Health Care Entities (Topic 954) - Presentation of Insurance Claims and Related Insurance Recoveries (ASU 2010-24), which further clarifies that health care entities should not net insurance recoveries against the related claim liabilities. In connection with the Company's adoption of ASU 2010-24, the Company recorded an increase to its other assets and reserves for self-insurance claims and other liabilities in the accompanying condensed consolidated balance sheet by \$10.5 million as of March 31, 2011 and December 31, 2010. The \$10.5 million increase to both other assets and reserves for self-insurance claims and other liabilities represents the Company's estimate of its recoveries for certain claims in excess of the Company's self-insured retention levels for workers compensation claims and professional and general liability claims. The adoption of ASU 2010-24 had no

impact on the Company s results of operations or cash flows.

The following is a summary of the line items impacted by the adoption of ASU 2010-24 in the Company s December 31, 2010 accompanying condensed consolidated balance sheet (in millions):

	As Originally Reported	Adjustments for the Adoption of ASU 2010-24	As Currently Reported
Other	\$ 9.7	\$ 10.5	\$ 20.2
Total assets	\$ 4,152.4	\$ 10.5	\$ 4,162.9
Reserves for self-insurance claims and other liabilities	\$ 121.3	\$ 10.5	\$ 131.8
Total liabilities	\$ 2,245.8	\$ 10.5	\$ 2,256.3
Total liabilities and equity	\$ 4,152.4	\$ 10.5	\$ 4,162.9

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 2. General and Administrative Costs

The majority of the Company s expenses are cost of revenue items. Costs that could be classified as general and administrative by the Company would include its corporate overhead costs, which were \$31.6 million and \$25.9 million for the three months ended March 31, 2011 and 2010, respectively.

Note 3. Fair Value of Financial Instruments

In accordance with Accounting Standards Codification (ASC) 825-10, Financial Instruments , the fair value of the Company s financial instruments are further described as follows.

Cash and Cash Equivalents, Accounts Receivable and Accounts Payable

The carrying amounts reported in the accompanying condensed consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term maturity of these instruments.

Long-Term Debt

The Company s term B loans (the Term B Loans) under its credit agreement with Citicorp North America, Inc., as administrative agent, the lenders from time to time party thereto, Bank of America, N.A., CIBC World Markets Corp., SunTrust Bank and UBS Securities LLC, as co-syndication agents and Citigroup Global Markets Inc. as sole lead arranger and sole book runner, as amended (the Credit Agreement), 6.625% unsecured senior notes due October 1, 2020 (the 6.625% Senior Notes), 3½% convertible senior subordinated notes due May 15, 2014 (the 3½% Notes) and 3¼% convertible senior subordinated debentures due August 15, 2025 (the 3¼% Debentures) are the Company s long-term debt instruments where the carrying amounts are different from their fair value. The carrying amount and fair value of these instruments as of March 31, 2011 and December 31, 2010 were as follows (in millions):

Carrying	g Amount	Fair Value			
March	December	March	December		
31,	31,	31,	31,		
2011	2010	2011	2010		
\$443.7	\$ 443 7	\$445.4	\$ 445.4		

Term B Loans

6.625% Senior Notes	\$400.0	\$ 400.0	\$408.0	\$ 398.0
31/2% Notes, excluding unamortized discount	\$575.0	\$ 575.0	\$616.7	\$ 579.3
31/4% Debentures, excluding unamortized discount	\$225.0	\$ 225.0	\$231.4	\$ 225.6

The fair values of the Company s Term B Loans and 6.625% Senior Notes were estimated based on the average bid and ask price as determined using published rates. The fair values of the Company s 3½% Notes and 3¼% Debentures were estimated based on the quoted market prices determined using the closing share price of the Company s common stock on in the indicated measurement dates.

Interest Rate Swap

The Company has designated its interest rate swap as a cash flow hedge instrument, which is recorded in the Company s accompanying condensed consolidated balance sheets at its fair value. The fair value of the Company s interest rate swap agreement is determined in accordance with ASC 815-10, Derivatives and Hedging (ASC 815-10), based on the amount at which it could be settled, which is referred to in ASC 815-10 as the exit price. The exit price is based upon observable market assumptions and appropriate valuation adjustments for credit risk. The Company has categorized its interest rate swap as Level 2 in the fair value hierarchy, which ASC 820-10, Fair Value Measurements and Disclosures (ASC 820-10), defines as observable market-based inputs or unobservable inputs that are corroborated by market data.

6

Long-Term Debt 15

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 3. Fair Value of Financial Instruments (continued)

The fair value of the Company s interest rate swap at March 31, 2011 and December 31, 2010 reflects a liability of \$4.0 million and \$7.9 million, respectively, and is included as a current liability under the caption other current liabilities in the accompanying condensed consolidated balance sheets. The Company s interest rate swap is further described in Note 5.

Note 4. Goodwill and Intangible Assets

Goodwill

The Company accounts for its acquisitions in accordance with ASC 805-10, Business Combinations using the acquisition method of accounting. Goodwill represents the excess of the cost of an acquired entity over the net amounts assigned to assets acquired and liabilities assumed. In accordance with ASC 350-10, Intangibles Goodwill and Other goodwill and intangible assets with indefinite lives are reviewed by the Company at least annually for impairment. The Company s business comprises a single operating reporting unit for impairment test purposes. For the purposes of these analyses, the Company s estimates of fair value are based on a combination of the income approach, which estimates the fair value of the Company based on its future discounted cash flows, and the market approach, which estimates the fair value of the Company based on comparable market prices. The Company performed its most recent annual impairment test as of October 1, 2010 and did not incur an impairment charge.

Intangible Assets

Summary of Intangible Assets

The following table provides information regarding the Company s intangible assets, which are included in the accompanying condensed consolidated balance sheets at March 31, 2011 and December 31, 2010 (in millions):

March 31, December 2011 31, 2010

Amortized intangible assets: Contract-based physician minimum revenue guarantees Gross carrying amount

\$ 87.9 \$ 87.2

Accumulated amortization	(41.3)	(37.9)
Net total	46.6	49.3
Non-competition agreements		
Gross carrying amount	29.3	29.3
Accumulated amortization	(12.7)	(12.0)
Net total	16.6	17.3
Total amortized intangible assets		
Gross carrying amount	117.2	116.5
Accumulated amortization	(54.0)	(49.9)
Net total	63.2	66.6
Indefinite-lived intangible assets:		
Certificates of need	6.5	6.5
Total intangible assets:		
Gross carrying amount	123.7	123.0
Accumulated amortization	(54.0)	(49.9)
Net total	\$ 69.7	\$ 73.1

TABLE OF CONTENTS

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 4. Goodwill and Intangible Assets (continued)

Contract-Based Physician Minimum Revenue Guarantees

The Company has committed to provide certain financial assistance pursuant to recruiting agreements, or physician minimum revenue guarantees, with various physicians practicing in the communities it serves. In consideration for a physician relocating to one of its communities and agreeing to engage in private practice for the benefit of the respective community, the Company may advance certain amounts of money to a physician to assist in establishing his or her practice.

The Company accounts for its physician minimum revenue guarantees in accordance with the provisions of ASC 460-10, Guarantees (ASC 460-10). In accordance with ASC 460-10, the Company records a contract-based intangible asset and a related guarantee liability for new physician minimum revenue guarantees. The contract-based intangible asset is amortized as a component of other operating expenses, in the accompanying condensed consolidated statements of operations, over the period of the physician contract, which typically ranges from four to five years. As of March 31, 2011 and December 31, 2010, the Company s liability for contract-based physician minimum revenue guarantees was \$15.9 million and \$18.0 million, respectively. These amounts are included in other current liabilities in the Company s accompanying condensed consolidated balance sheets.

Non-Competition Agreements

The Company has entered into non-competition agreements with certain physicians and other individuals which are amortized on a straight-line basis over the term of the agreements.

Certificates of Need

The construction of new facilities, the acquisition or expansion of existing facilities and the addition of new services and certain equipment at the Company s facilities may be subject to state laws that require prior approval by state regulatory agencies. These certificate of need laws generally require that a state agency determine the public need and give approval prior to the construction or acquisition of facilities or the addition of new services.

Note 5. Interest Rate Swap

The Company has an interest rate swap agreement with Citibank, N.A. (Citibank) as counterparty that matures on May 30, 2011. The interest rate swap agreement requires the Company to make quarterly fixed rate payments to

Citibank calculated on a notional amount as set forth in the table below at an annual fixed rate of 5.585% while Citibank is obligated to make quarterly floating payments to the Company based on the three-month LIBOR on the same referenced notional amount. Notwithstanding the terms of the interest rate swap transaction, the Company is ultimately obligated for all amounts due and payable under its Credit Agreement.

The following table provides information regarding the notional amounts in effect for the indicated date ranges for the Company's interest rate swap agreement:

The Company entered into the interest rate swap agreement to mitigate the floating interest rate risk on a portion of its outstanding borrowings under its Credit Agreement. In accordance with ASC 815-10 the Company is required to recognize all derivative instruments as either assets or liabilities at fair value in its balance sheets. In accordance with ASC 815-10, the Company designates its interest rate swap as a cash flow

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 5. Interest Rate Swap (continued)

hedge. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (OCI) and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. The Company assesses the effectiveness of its interest rate swap on a quarterly basis. The Company completed its quarterly assessments for the three months ended March 31, 2011 and 2010 and determined the hedge to be effective.

As of March 31, 2011 and December 31, 2010, the fair value and line item caption of the Company s interest rate swap derivative instrument were as follows (in millions):

	Balance Sheet Location	March December 31, 2011 31, 2010
Derivative designated as a hedging instrument under ASC 815-10:		
Interest rate swap	Other current liabilities	\$ 4.0 \$ 7.9

The following table shows the effect of the Company s interest rate swap derivative instrument qualifying and designated as a hedging instrument in cash flow hedges for the three months ended March 31, 2011 and 2010 (in millions):

Amount of	Location of gain	Amount of
gain (loss)	(loss) recognized	gain (loss)
recognized in	in Income on	recognized in
OCI on	Derivative	Income on
Derivative	(Ineffective Portion	Derivative
(Effective	and Amount	(Ineffective
Portion)	Excluded from	Portion and
	Effectiveness	Amount
	Testing)	Excluded from
		Effectiveness

	March 31,		Testing) March 31,		
	2011 2010		2011	2010	
Derivative in ASC 815-10 cash flow hedging relationships:					
Interest rate swap	\$3.9 \$ 3.8	Interest expense,	\$	\$	

Since the Company s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation model that involves a discounted cash flow analysis on the expected cash flows. This cash flow analysis reflects the contractual terms of the interest rate swap agreement, including the period to maturity, and uses observable market-based inputs, including the three-month LIBOR forward interest rate curve. The fair value of the Company s interest rate swap agreement is determined by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates based on the observable market three-month LIBOR forward interest rate curve and the notional amount being hedged.

The observable market three-month LIBOR forward interest rate used was 0.31050% at May 30, 2011. In addition, the Company incorporates credit valuation adjustments to appropriately reflect both its own and Citibank's non-performance or credit risk in the fair value measurements. The interest rate swap agreement exposes the Company to credit risk in the event of non-performance by Citibank. However, the Company does not anticipate non-performance by Citibank. The majority of the inputs used to value its interest rate swap agreement, including the three-month LIBOR forward interest rate curve and market perceptions of the Company's credit risk used in the credit valuation adjustments, are observable inputs available to a market participant. As a result, the Company has determined that the interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with ASC 820-10.

TABLE OF CONTENTS

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 6. Common Stock in Treasury and Repurchases of Common Stock

In August 2009, the Company s Board of Directors authorized the repurchase of up to \$100.0 million of outstanding shares of the Company s common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints and other factors (the 2009 Repurchase Plan). The 2009 Repurchase Plan expired in February 2011. In connection with the 2009 Repurchase Plan, the Company repurchased approximately 0.2 million shares for an aggregate purchase price, including commissions, of \$5.2 million at an average purchase price of \$32.84 per share for the three months ended March 31, 2010. There were no repurchases made in accordance with the 2009 Repurchase Plan during the three months ended March 31, 2011. The Company has designated the shares repurchased in accordance with the 2009 Repurchase Plan as treasury stock.

In September 2010, the Company s Board of Directors authorized the repurchase of up to an additional \$150.0 million of outstanding shares of the Company s common stock either in open market purchases, privately negotiated transactions, accelerated share repurchase programs or other transactions (the 2010 Repurchase Plan). The 2010 Repurchase Plan expires in March 2012. The Company is not obligated to repurchase any specific number of shares under the 2010 Repurchase Plan. There were no repurchases made in accordance with the 2010 Repurchase Plan during the three months ended March 31, 2011.

Additionally, the Company redeems shares from employees for minimum statutory tax withholding purposes upon vesting of certain stock awards granted pursuant to its Amended and Restated 1998 Long-Term Incentive Plan (LTIP) and Amended and Restated Management Stock Purchase Plan (MSPP). The Company redeemed approximately 0.1 million shares of certain vested LTIP and MSPP shares during each of the three months ended March 31, 2011 and 2010 for an aggregate price of \$5.5 million and \$3.8 million, respectively. The Company has designated these shares as treasury stock.

Note 7. Stock-Based Compensation

Overview

The Company issues stock-based awards, including stock options and other stock-based awards (nonvested stock, restricted stock, restricted stock units, performance shares and deferred stock units) to certain officers, employees and non-employee directors in accordance with the Company s various stockholder-approved stock-based compensation plans. The Company accounts for its stock-based awards in accordance with the provisions of ASC 718-10

Compensation Stock Compensation , (ASC 718-10) and accordingly recognizes compensation expense over each of the stock-based award s requisite service period based on the estimated grant date fair value.

Stock Options

The Company granted stock options to purchase 717,365 and 1,231,750 shares of the Company s common stock to certain officers and employees in accordance with the LTIP during the three months ended March 31, 2011 and 2010, respectively. Options to purchase shares granted to the Company s officers and employees in accordance with the LTIP were granted with an exercise price equal to the fair market value of the Company s common stock on the day prior to the grant date. The options granted during the three months ended March 31, 2011 and 2010 become ratably exercisable beginning one year from the date of grant to three years after the date of grant and expire ten years from the date of grant.

The Company estimated the fair value of stock options granted using the Hull-White II (HW-II) lattice option valuation model and a single option award approach. The Company uses the HW-II because it considers characteristics of fair value option pricing, such as an option s contractual term and the probability of exercise before the end of the contractual term. In addition, the complications surrounding the expected term of an option are material, as indicated in ASC 718-10. Given the Company s relatively large pool of unexercised options, the Company believes a lattice model that specifically addresses this fact and models a

10

Overview 23

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 7. Stock-Based Compensation (continued)

full term of exercises is the most appropriate and reliable means of valuing its stock options. The Company is amortizing the fair value on a straight-line basis over the requisite service period of the awards, which is the vesting period of three years. The stock options vest 33.3% on each grant anniversary date over three years of continued employment.

The following table shows the weighted average assumptions the Company used to develop the fair value estimates under its HW-II option valuation model and the resulting estimates of weighted-average fair value per share of stock options granted during the three months ended March 31, 2011 and 2010:

	Three Months Ended				
	March 31				
	2011				
Expected volatility	36.0	%	40.0	%	
Risk free interest rate (range)	0.11%	3.5%	0.06%	3.69%	
Expected dividends					
Average expected term (years)	5.3		5.4		
Fair value per share of stock options granted	\$ 11.77		\$ 11.22		

The total intrinsic value of stock options exercised during the three months ended March 31, 2011 and 2010 was \$5.5 million and \$2.5 million, respectively. The Company received \$17.5 million and \$9.2 million in cash from stock option exercises for the three months ended March 31, 2011 and 2010, respectively. The actual tax benefit realized for the tax deductions from stock option exercises totaled \$0.3 million and \$0.1 million for the three months ended March 31, 2011 and 2010, respectively.

As of March 31, 2011, there was \$16.3 million of total estimated unrecognized compensation cost related to stock option compensation arrangements. Total estimated unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. The Company expects to recognize that cost over a weighted average period of 1.6 years.

Other Stock-Based Awards

The Company granted 435,694 and 447,372 shares of nonvested stock awards to certain officers and employees in accordance with the LTIP and MSPP during the three months ended March 31, 2011 and 2010, respectively. The fair

value of other stock-based awards is determined based on the closing price of the Company s common stock on the day prior to the grant date. The nonvested stock awards granted during the three months ended March 31, 2011 and 2010 have either cliff-vesting periods from the grant date of three years or ratable vesting periods beginning one year from the date of grant to three years after the date of grant.

Of the nonvested stock awards granted during the three months ended March 31, 2011 and 2010, 297,000 and 310,500 were performance-based, respectively. In addition to requiring continuing service of an employee, the vesting of these nonvested stock awards is contingent upon the satisfaction of certain financial goals, specifically related to the achievement of targeted annual revenues and earnings goals within a three-year period. In accordance with the LTIP, if these goals are achieved, the nonvested stock awards will cliff-vest three years after the grant date. The performance criteria for performance-based nonvested stock awards granted during the three months ended March 31, 2010 have been certified as met by the Compensation Committee of the Company s Board of Directors, however, these awards are still subject to continuing service requirements and the three year cliff-vesting provisions. For purposes of estimating compensation expense for the performance-based nonvested stock awards granted during the three months ended March 31, 2011, the Company has assumed that the performance goals will be achieved. If the performance goals are not met for

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 7. Stock-Based Compensation (continued)

the performance-based awards granted during the three months ended March 31, 2011, no compensation expense will be recognized, and any previously recognized compensation expense will be reversed.

Notwithstanding the specific grant vesting requirements, nonvested stock awards and performance-based awards granted under the LTIP become fully vested upon the death or disability of the participant. Additionally, in the event of termination without cause of a participant, the nonvested stock awards and performance-based awards otherwise subject to cliff-vesting become vested in a percentage equal to the number of full months of continuous employment following the date of grant through the date of termination divided by the total number of months in the vesting period, and in the case of performance-based awards, only in the event that the performance goals are attained.

The Company received \$0.7 million and \$0.6 million for the issuance of nonvested stock in accordance with the MSPP during the three months ended March 31, 2011 and 2010, respectively.

As of March 31, 2011, there was \$23.0 million of total estimated unrecognized compensation cost related to other stock-based awards granted in accordance with the LTIP and MSPP. Total estimated unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. The Company expects to recognize that cost over a weighted average period of 2.1 years.

The following table summarizes the Company s total stock-based compensation expense as well as the total recognized tax benefits related thereto for the three months ended March 31, 2011 and 2010 (in millions):

	Three Months Ended
	March 31,
	2011 2010
Other stock-based awards	\$ 3.2 \$ 3.8
Stock options	2.5 2.0
Total stock-based compensation expense	\$ 5.7 \$ 5.8
Tax benefits on stock-based compensation expense	\$ 2.4 \$ 2.3

The Company did not capitalize any stock-based compensation cost during the three months ended March 31, 2011 or 2010. As of March 31, 2011, there was \$39.3 million of total estimated unrecognized compensation cost related to all of the Company s stock-based compensation arrangements. Total estimated unrecognized compensation cost may be adjusted for future changes in estimated forfeitures. The Company expects to recognize that cost over a

weighted-average period of 1.9 years.

Note 8. Commitments and Contingencies

Legal Proceedings and General Liability Claims

The Company is, from time to time, subject to claims and suits arising in the ordinary course of business, including claims for damages for personal injuries, medical malpractice, breach of contracts, wrongful restriction of or interference with physicians—staff privileges and employment related claims. In certain of these actions, plaintiffs request payment for damages, including punitive damages that may not be covered by insurance. The Company is currently not a party to any pending or threatened proceeding, which, in management—s opinion, would have a material adverse effect on the Company—s business, financial condition or results of operations.

In May 2009, the Company s hospital in Andalusia, Alabama (Andalusia Regional Hospital) produced documents responsive to a request received from the U.S. Attorney s Office for the Western District of New York regarding an investigation they are conducting with respect to the billing of kyphoplasty

TABLE OF CONTENTS

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 8. Commitments and Contingencies (continued)

procedures. Kyphoplasty is a surgical spine procedure that returns a compromised vertebra (either from trauma or osteoporotic disease process) to its previous height, reducing or eliminating severe pain. It has been reported that other unaffiliated hospitals and hospital operators in multiple states have received similar requests for information. The Company believes that this investigation is related to the May 22, 2008 qui tam settlement between the same U.S. Attorney s Office and the manufacturer and distributor of the product used in performing the kyphoplasty procedure.

Based on a review of the number of the kyphoplasty procedures performed at all of the Company s other hospitals, as part of its effort to cooperate with the U.S. Attorney s Office, by letter dated January 20, 2010 the Company s management identified to the U.S. Attorney s Office four additional facilities at which the number of inpatient kyphoplasty procedures approximated those performed at Andalusia Regional Hospital. The Company s management has completed its review of the relevant medical records and is continuing to cooperate with the government s investigation.

Physician Commitments

The Company has committed to provide certain financial assistance pursuant to recruiting agreements with various physicians practicing in the communities it serves. In consideration for a physician s relocating to one of its communities and agreeing to engage in private practice for the benefit of the respective community, the Company may advance certain amounts of money to a physician, normally over a period of one year, to assist in establishing the physician s practice. The Company has committed to advance a maximum amount of approximately \$28.9 million at March 31, 2011. The actual amount of such commitments to be subsequently advanced to physicians is estimated at \$15.9 million and often depends upon the financial results of a physician s private practice during the guarantee period. Generally, amounts advanced under the recruiting agreements may be forgiven pro rata over a period of 36 to 48 months contingent upon the physician continuing to practice in the respective community. Pursuant to the Company s standard physician recruiting agreement, any breach or non-fulfillment by a physician under the physician recruiting agreement gives the Company the right to recover any payments made to the physician under the agreement.

Capital Expenditure Commitments

The Company is reconfiguring some of its facilities to accommodate patient services more effectively, permit additional patient volume and a greater variety of services, and implementing various information system initiatives in its efforts to comply with the Health Information Technology for Economic and Clinical Health Act. The Company has incurred \$62.3 million in uncompleted projects as of March 31, 2011, which is included as construction in

progress in the Company s accompanying condensed consolidated balance sheet. At March 31, 2011, the Company had uncompleted projects with an estimated cost to complete and equip of approximately \$144.5 million. The Company is subject to annual capital expenditure commitments in connection with several of its facilities.

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 9. Earnings (Loss) Per Share

The following table sets forth the computation of basic and diluted earnings (loss) per share for the three months ended March 31, 2011 and 2010 (dollars and shares in millions, except per share amounts):

	Three N	Months
	Ended I	March 31,
	2011	2010
Numerator for basic and diluted earnings per share attributable to LifePoint		
Hospitals, Inc.:		
Income from continuing operations	\$46.5	\$44.2
Less: Net income attributable to noncontrolling interests	(0.7)	(0.9)
Income from continuing operations attributable to LifePoint	45.8	43.3
Hospitals, Inc. stockholders	45.0	45.5
Income (loss) from discontinued operations, net of income taxes	0.3	(0.4)
Net income attributable to LifePoint Hospitals, Inc.	\$46.1	\$42.9
Denominator:		
Weighted average shares outstanding basic	50.2	53.2
Effect of dilutive securities: stock options and other stock-based awards	1.4	1.3
Weighted average shares outstanding diluted	51.6	54.5
Basic earnings (loss) per share attributable to LifePoint Hospitals, Inc.		
stockholders:		
Continuing operations	\$0.91	\$0.82
Discontinued operations	0.01	(0.01)
Net income	\$0.92	\$0.81
Diluted earnings (loss) per share attributable to LifePoint Hospitals, Inc.		
stockholders:		
Continuing operations	\$0.89	\$0.80
Discontinued operations		(0.01)
Net income	\$0.89	\$0.79
approx 3 316% Notes and 31/% Departures are included in the colculation of di	lutad aarr	inge par el

The Company s 3½% Notes and 3¼% Debentures are included in the calculation of diluted earnings per share whether or not the contingent requirements have been met for conversion if the conversion price of \$51.79 and \$61.22, respectively, is less than the average market price of the Company s common stock for the period. Upon conversion, the par value is settled in cash, and only the conversion premium is settled in shares of the Company s common stock.

The impact of the 3½% Notes and 3¼% Debentures has been excluded because the effects would have been anti-dilutive for the three months ended March 31, 2011 and 2010.

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 10. Guarantor and Non-Guarantor Supplementary Information

The Company s 6.625% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by substantially all of the Company s existing subsidiaries that guarantee the Company s Credit Agreement. The following presents the condensed consolidating financial information for the parent issuer, guarantor subsidiaries, non-guarantor subsidiaries, certain eliminations and the Company for the three months ended March 31, 2011 and 2010 and as of March 31, 2011 and December 31, 2010:

LIFEPOINT HOSPITALS, INC. Condensed Consolidating Statements of Operations For the Three Months Ended March 31, 2011 (In millions)

	Parent Issuer	Guarantors Non-Guaranto imination Consolida				
Revenues	\$	\$808.3	\$ 80.3	\$	\$888.6	
Salaries and benefits	5.7	304.5	24.2		334.4	
Supplies		105.2	13.5		118.7	
Other operating expenses		150.4	11.2		161.6	
Provision for doubtful accounts		119.7	10.4		130.1	
Equity in earnings of affiliates	(62.3)			62.3		
Depreciation and amortization		36.2	3.5		39.7	
Interest expense, net	11.6	17.3	0.3		29.2	
Management (income) fees		(2.4)	2.4			
	(45.0)	730.9	65.5	62.3	813.7	
Income from continuing operations before						
income	45.0	77.4	14.8	(62.3)	74.9	
taxes						
Provision for income taxes	(1.1)	29.5			28.4	

Income from continuing operations	46.1	47.9		14.8		(62.3)	46.5	
Income from discontinued operations, net of taxes:		0.3						0.3	
Net income	46.1	48.2		14.8		(62.3)	46.8	
Less: Net income attributable to noncontrolling interests		(0.2)	(0.5)			(0.7)
Net income attributable to LifePoint Hospitals, Inc.	\$46.1	\$48.0		\$ 14.3		\$ (62.3)	\$ 46.1	

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 10. Guarantor and Non-Guarantor Supplementary Information (continued)

LIFEPOINT HOSPITALS, INC. Condensed Consolidating Statements of Operations For the Three Months Ended March 31, 2010 (In millions)

	Parent Issuer	Guarantors Non-Guaranto imination Consolidate					
Revenues	\$	\$708.8	\$ 77.4	\$	\$ 786.2		
Salaries and benefits	5.8	274.0	23.5		303.3		
Supplies		95.8	12.6		108.4		
Other operating expenses	0.2	128.7	11.5		140.4		
Provision for doubtful accounts		93.3	8.8		102.1		
Equity in earnings of affiliates	(58.1)			58.1			
Depreciation and amortization		32.5	3.6		36.1		
Interest expense, net	9.5	15.6			25.1		
Management (income) fees		(2.2)	2.2				
	(42.6)	637.7	62.2	58.1	715.4		
Income from continuing operations before							
income	42.6	71.1	15.2	(58.1) 70.8		
taxes							
Provision for income taxes	(0.3)	26.9			26.6		
Income from continuing operations	42.9	44.2	15.2	(58.1) 44.2		
Loss from discontinued operations, net of		(0.4)			(0.4)		
income taxes		(0.4			(0.4		
Net income	42.9	43.8	15.2	(58.1) 43.8		
Less: Net income attributable to noncontrolling interests		(0.2)	(0.7)	(0.9)		

Net income attributable to LifePoint Hospitals, Inc.

\$42.9 \$43.6

\$ 14.5

\$ (58.1) \$ 42.9

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 10. Guarantor and Non-Guarantor Supplementary Information (continued)

LIFEPOINT HOSPITALS, INC. Condensed Consolidating Balance Sheets March 31, 2011 (In millions)

	Parent Issuer	Guarantors	Non-Guaran	to F diminations	Consolidated
ASSETS					
Current assets:					
Cash and cash equivalents	\$	\$266.1	\$ 10.1	\$	\$276.2
Accounts receivable, net		365.5	34.4		399.9
Inventories		75.4	8.7		84.1
Prepaid expenses		16.5	0.9		17.4
Deferred tax assets	106.9				106.9
Other current assets		25.9			25.9
	106.9	749.4	54.1		910.4
Property and equipment:					
Land		74.1	12.5		86.6
Buildings and improvements		1,401.8	133.2		1,535.0
Equipment		906.3	66.6		972.9
Construction in progress		56.6	5.7		62.3
		2,438.8	218.0		2,656.8
Accumulated depreciation		(899.3)	(74.0)		(973.3)
		1,539.5	144.0		1,683.5
Deferred loan costs, net	25.7				25.7
Intangible assets, net		48.2	21.5		69.7
Investments in subsidiaries	1,318.2			(1,318.2)	

Edgar Filing: LIFEPOINT HOSPITALS, INC. - Form 10-Q

Other	1.0	14.9	1.7			17.6
Goodwill		1,413.7	137.5			1,551.2
Total assets	\$1,451.8	\$3,765.7	\$ 358.8		\$(1,318.2)	\$4,258.1
LIABILITIES AND EQUITY						
Current liabilities:						
Accounts payable	\$	\$88.3	\$ 5.9		\$	\$94.2
Accrued salaries		74.8	5.8			80.6
Accrued interest	25.6	0.1				25.7
Income taxes payable	25.5					25.5
Other current liabilities	4.0	97.9	11.6			113.5
Current maturities of long-term debt		1.3				1.3
	55.1	262.4	23.3			340.8
Long-term debt	1,569.8	6.3				1,576.1
Intercompany	(2,363.0)	2,412.7	(49.7)		
Deferred income tax liabilities	213.4					213.4
Reserves for self-insurance claims and		110.8	21.7			132.5
other liabilities	40.4					
Long-term income tax liability	19.4	. =	.			19.4
Total liabilities	(505.3)	2,792.2	(4.7)		2,282.2
Redeemable noncontrolling interests			15.3			15.3
Total LifePoint Hospitals, Inc.	1,957.1	972.3	345.9		(1,318.2)	1,957.1
stockholders equity	,				() /	
Noncontrolling interests		1.2	2.3			3.5
Total equity	1,957.1	973.5	348.2		(1,318.2)	1,960.6
Total liabilities and equity	\$1,451.8	\$3,765.7	\$ 358.8		\$(1,318.2)	\$4,258.1

17

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 10. Guarantor and Non-Guarantor Supplementary Information (continued)

LIFEPOINT HOSPITALS, INC. Condensed Consolidating Balance Sheets December 31, 2010 (In millions)

	Parent Issuer	Guarantors	Non-Gua	ranto E slimina	ations Consolidated
ASSETS					
Current assets:					
Cash and cash equivalents	\$	\$197.1	\$ 10.3	\$	\$207.4
Accounts receivable, net		358.4	28.9		387.3
Inventories		75.9	8.7		84.6
Prepaid expenses		13.6	0.3		13.9
Income taxes receivable	5.5				5.5
Deferred tax assets	99.7				99.7
Other current assets		24.5	0.2		24.7
	105.2	669.5	48.4		823.1
Property and equipment:					
Land		73.5	12.4		85.9
Buildings and improvements		1,399.8	133.1		1,532.9
Equipment		883.7	66.5		950.2
Construction in progress		36.6	2.8		39.4
		2,393.6	214.8		2,608.4
Accumulated depreciation		(868.6)	(71.2)	(939.8)
		1,525.0	143.6		1,668.6
Deferred loan costs, net	27.2				27.2
Intangible assets, net		50.5	22.6		73.1

Edgar Filing: LIFEPOINT HOSPITALS, INC. - Form 10-Q

Investments in subsidiaries Other Goodwill	1,255.9	18.2 1,413.2	2.0 137.5	(1,255.9) 20.2 1,550.7
Total assets	\$1,388.3	\$3,676.4	\$ 354.1	\$(1,255.9) \$4,162.9
LIABILITIES AND EQUITY				
Current liabilities:				
Accounts payable	\$	\$83.0	\$ 6.0	\$ \$89.0
Accrued salaries		96.0	5.4	101.4
Accrued interest	16.0			16.0
Other current liabilities	7.9	96.2	12.4	116.5
Current maturities of long-term debt		1.4		1.4
	23.9	276.6	23.8	324.3
Long-term debt	1,563.9	6.6		1,570.5
Intercompany	(2,316.7)	2,361.2	(44.5)
Deferred income tax liabilities	211.2			211.2
Reserves for self-insurance claims and	1	107.0	24.8	131.8
other liabilities		10710	20	
Long-term income tax liability	18.5			18.5
Total liabilities	(499.2)	2,751.4	4.1	2,256.3
Redeemable noncontrolling			15.3	15.3
interests Tatal Life Point Heavitals Line				
Total LifePoint Hospitals, Inc. stockholders equity	1,887.5	923.7	332.2	(1,255.9) 1,887.5
Noncontrolling interests		1.3	2.5	3.8
Total equity	1,887.5	925.0	334.7	(1,255.9) 1,891.3
Total liabilities and equity	\$1,388.3	\$3,676.4	\$ 354.1	\$(1,255.9) \$4,162.9

18

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 10. Guarantor and Non-Guarantor Supplementary Information (continued)

LIFEPOINT HOSPITALS, INC. Condensed Consolidating Statements of Cash Flows For the Three Months Ended March 31, 2011 (In millions)

	Parent Issuer	Guarar	ntor	s Non-Gı	ıaran t6li mina	atio	n€onsoli	dated
Cash flows from operating activities:								
Net income	\$46.1	\$48.2		\$ 14.8	\$ (62.3)	\$ 46.8	
Adjustments to reconcile net income to net								
cash provided by operating activities:								
Net income from discontinued operations		(0.3))				(0.3)
Equity in earnings of affiliates	(62.3)				62.3			
Stock-based compensation	5.7						5.7	
Depreciation and amortization		36.2		3.5			39.7	
Amortization of physician minimum revenue		4.1		0.5			16	
guarantees		4.1		0.5			4.6	
Amortization of convertible debt discounts	5.9						5.9	
Amortization of deferred loan costs	1.5						1.5	
Deferred income tax benefit	(2.7)						(2.7)
Reserve for self-insurance claims, net of		7.0		(2.1	`		4.7	
payments		7.8		(3.1)		4.7	
Increase (decrease) in cash from operating								
assets and liabilities, net of effects from								
acquisitions and divestitures:								
Accounts receivable		(9.0)	(5.5)		(14.5)
Inventories and other current assets		(1.4)	(0.4)		(1.8)

Edgar Filing: LIFEPOINT HOSPITALS, INC. - Form 10-Q

	0.6	(145)	(0.5	`	(F. A	,
Accounts payable and accrued expenses	9.6	(14.5)	(0.5)	(5.4)
Income taxes payable /receivable	31.0	0.5	0.2		31.0	
Other	(0.2)	0.5	0.3		0.6	
Net cash provided by operating	34.6	71.6	9.6		115.8	
activities continuing operations						
Net cash provided by operating		0.2			0.2	
activities discontinued operations	24.6	71.0	0.6		1160	
Net cash provided by operating activities	34.6	71.8	9.6		116.0	
Cash flows from investing activities:		(50.6.)	(2.2	,	(55.0	,
Purchase of property and equipment		(52.6)	(3.3)	(55.9)
Acquisitions, net of cash acquired	(1.0.)	(1.7)			(1.7)
Other	(1.0)	0.1	(2.2		(0.9)
Net cash used in investing activities	(1.0)	(54.2)	(3.3)	(58.5)
Cash flows from financing activities:						
Repurchases of common stock	(5.5)				(5.5)
Proceeds from exercise of stock options	17.5				17.5	
Proceeds from employee stock purchase plans	0.7				0.7	
Proceeds from (distributions to) noncontrolling		0.3	(1.3)	(1.0)
interests		0.5	(1.5	,	(1.0	,
Change in intercompany balances with	(46.3)	51.5	(5.2)		
affiliates, net	(1010)		(0.2	,		
Capital lease payments and other		(0.4)			(0.4))
Net cash (used in) provided by financing	(33.6)	51.4	(6.5)	11.3	
activities	(33.0)			,		
Change in cash and cash equivalents		69.0	(0.2))	68.8	
Cash and cash equivalents at beginning of		197.1	10.3		207.4	
period						
Cash and cash equivalents at end of period	\$	\$266.1	\$ 10.1		\$ \$ 276.2	

LIFEPOINT HOSPITALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS March 31, 2011 Unaudited

Note 10. Guarantor and Non-Guarantor Supplementary Information (continued)

LIFEPOINT HOSPITALS, INC. Condensed Consolidating Statements of Cash Flows For the Three Months Ended March 31, 2010 (In millions)

	Parent Issuer	Guaranton	rs Non-Gı	ıarant Eli minatic	n C onsoli	dated
Cash flows from operating activities:						
Net income	\$42.9	\$43.8	\$ 15.2	\$ (58.1)	\$43.8	
Adjustments to reconcile net income to net						
cash provided by operating activities:						
Net loss from discontinued operations		0.4			0.4	
Equity in earnings of affiliates	(58.1)			58.1		
Stock-based compensation	5.8				5.8	
Depreciation and amortization		32.5	3.6		36.1	
Amortization of physician minimum revenue		2.6	0.2		2.0	
guarantees		3.6	0.3		3.9	
Amortization of convertible debt discounts	5.5				5.5	
Amortization of deferred loan costs	2.4				2.4	
Deferred income tax benefit	(4.1)				(4.1)
Reserve for self-insurance claims, net of		<i>(</i> 1	(2.0	`	4.1	
payments		6.1	(2.0)	4.1	
Increase (decrease) in cash from operating						
assets and liabilities, net of effects from						
acquisitions and divestitures:						
Accounts receivable		(19.9)	(4.8)	(24.7)
Inventories and other current assets	1.2	(0.9)	(0.7)	(0.4)

Edgar Filing: LIFEPOINT HOSPITALS, INC. - Form 10-Q

Accounts payable and accrued expenses Income taxes payable /receivable Other Net cash provided by operating	3.7 29.6 0.2	(22.5) (0.1) 43.0	(0.2)	(19.0) 29.6 0.1 83.5	
activities continuing operations Net cash used in operating activities discontinued operations	29.1 (0.2)	43.0	11.4		(0.2)	
Net cash provided by operating activities Cash flows from investing activities:	28.9	43.0	11.4		83.3	
Purchase of property and equipment Acquisitions, net of cash acquired Net cash used in investing activities		(32.4) (4.2) (36.6)	(1.6 (12.7 (14.3)))	(34.0) (16.9) (50.9)	
Cash flows from financing activities: Repurchases of common stock Payment of debt refinance costs Proceeds from exercise of stock options Proceeds from employee stock purchase plans	(9.0) (4.4) 9.2 0.6				(9.0) (4.4) 9.2 0.6	
Proceeds from (distributions to) noncontrolling interests Issuance of redeemable noncontrolling interests		0.4	(0.9 4.2)	(0.5)	
Change in intercompany balances with affiliates, net	(25.3)	27.5	(2.2)		
Capital lease payments and other Net cash (used in) provided by financing activities	(28.9)	(0.2) 27.7	(0.1 1.0)	(0.3) (0.2)	
Change in cash and cash equivalents Cash and cash equivalents at beginning of period		34.1 178.4	(1.9 8.8)	32.2 187.2	
Cash and cash equivalents at end of period	\$	\$212.5	\$ 6.9	\$	\$ 219.4	

Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.

We recommend that you read this discussion together with our unaudited condensed consolidated financial statements and related notes included elsewhere in this report, as well as our Annual Report on Form 10-K for the year ended December 31, 2010 (the 2010 Annual Report on Form 10-K). Unless otherwise indicated, all relevant financial and statistical information included herein relates to our continuing operations. Additionally, unless the context indicates otherwise, LifePoint Hospitals, Inc. and its subsidiaries are referred to in this section as we, our, or us.

We make forward-looking statements in this report, other reports and in statements we file with the SEC and/or release to the public. In addition, our senior management makes forward-looking statements orally to analysts, investors, the media and others. Broadly speaking, forward-looking statements include: projections of our revenues, net income, earnings per share, capital expenditures, cash flows, debt repayments, interest rates, operating statistics and data or other financial items; descriptions of plans or objectives of our management for future operations, services or growth plans including acquisitions, divestitures, business strategies and initiatives; interpretations of Medicare and Medicaid laws and regulations and their effect on our business; and descriptions of assumptions underlying or relating to any of the foregoing.

In this report, for example, we make forward-looking statements, including statements discussing our expectations about: future financial performance and condition; future liquidity and capital resources; future cash flows; existing and future debt; our strategic goals; future acquisitions; our business strategy and operating philosophy, including an evaluation of growth strategies for existing markets and for potential acquisitions; effects of competition in a hospital s market; costs of providing care to our patients; changes in interest rates; our compliance with new and existing laws and regulations as well as costs and benefits associated with compliance; the impact of national healthcare reform; the performance of counterparties to our agreements; effect of credit ratings; professional fees; industry and general economic trends; reimbursement changes; patient volumes and related revenues; claims and legal actions relating to professional liabilities, governmental investigations and other matters; and physician recruiting and retention.

Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements often include words such as can, could. may, estimate. continue or similar expressions. You should i expect. project, seek. anticipate, intend. target, on forward-looking statements, which give our expectations about the future and are not guarantees. Forward-looking statements speak only as of the date they are made. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict such new risk factors nor can we assess the impact, if any, of such new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those expressed or implied by any forward-looking statement. We do not undertake any obligation to update our forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.

There are several factors, some beyond our control that could cause results to differ significantly from our expectations. Some of these factors as well as other factors such as market, operational, liquidity, interest rate and other risks are described in Part I, Item 1A. *Risk Factors* and Part II, Item 7A. *Quantitative and Qualitative Disclosures about Market Risk* of our 2010 Annual Report on Form 10-K. Any factor described in this report and in our 2010 Annual Report on Form 10-K could by itself, or together with one or more factors, adversely affect our business, results of operations and/or financial condition. There may be factors not described in this report or in our 2010 Annual Report on Form 10-K that could also cause results to differ from our expectations.

Overview

We operate general acute care hospitals in non-urban communities in the United States. At March 31, 2011, on a consolidated basis, we operated 52 hospital campuses in 17 states, having a total of 5,798 licensed beds. We generate revenues primarily through hospital services offered at our facilities. We generated \$888.6 million and \$786.2 million in revenues from continuing operations during the three months ended March, 31 2011 and 2010, respectively. For the three months ended March 31, 2011 and 2010, we derived 42.9% and 43.3%, respectively, of our revenues from the Medicare and Medicaid programs, collectively.

21

Overview 45

Payments made to our hospitals pursuant to the Medicare and Medicaid programs for services rendered rarely exceed our costs for such services. The hospital industry is also enduring a period where the costs of providing care are rising faster than reimbursement rates. As a result, we rely largely on payments made by private or commercial payors, together with certain limited services provided to Medicare recipients, to generate an operating profit. This places a premium on efficient operation, the ability to reduce or control costs and the need to leverage the benefits of our organization across all of our hospitals.

Our hospitals typically provide the range of medical and surgical services commonly available in hospitals in non-urban markets, although the services provided at any specific hospital depend on factors such as community need for the service, whether physicians necessary to operate the service line safely are members of the medical staff of that hospital, whether the service might be economically viable, and any contractual or certificate of need restrictions that might exist.

Competitive and Structural Environment

The environment in which our hospitals operate is extremely competitive. Many of our communities are experiencing slow growth, and in some cases, population losses. The economies of our communities are also more sensitive to economic downturns in the manufacturing sector than the United States generally.

Our hospitals face competition from other acute care hospitals, including larger tertiary hospitals located in larger markets and/or affiliated with universities; specialty hospitals that focus on one or a small number of very lucrative service lines but that are not required to operate emergency departments; stand-alone centers at which surgeries or diagnostic tests can be performed; and physicians on the medical staffs of our hospitals. In many cases, our competitors focus on the service lines that offer the highest margins. By doing so, our competitors can potentially draw the best-paying business out of our hospitals. This, in turn, can reduce the overall operating profit of our hospitals as we are often obligated to offer service lines that operate at a loss or that have much lower profit margins. We continue to see the shift of increasingly complex procedures from the inpatient to the outpatient setting and have also seen growth in the general shift of lower acuity procedures to physician offices and other non-hospital outpatient settings. These trends have, to some extent, offset our efforts to improve equivalent admission rates at many of our hospitals.

Our hospitals also face extreme competition in their efforts to recruit and retain physicians on their medical staffs. It is widely recognized that the United States has a shortage of physicians in certain practice areas, including specialists such as cardiologists, oncologists, urologists and orthopedists, in various areas of the country. This fact, and our ability to overcome these shortages, is directly relevant to our growth strategies because cardiologists, oncologists, urologists and orthopedists are often the physicians in highest demand in communities where our hospitals are located. Larger tertiary medical centers are acquiring physician practices and employ physicians in some of our communities. While physicians in these practices may continue to be members of the medical staffs of our hospitals, they may be less likely to refer patients to our hospitals over time.

We believe other key factors in our competition for patients is the quality of our patient care and the perception of that quality in the communities where our hospitals are located, which may be influenced by, among other things, the technology, service lines and capital improvements made at our facilities. The quality of care, and our communities perception of that quality, may also be influenced by the skills and experience of our non-physician employees involved in patient care.

Business Strategy

In order to achieve growth in patient volumes, revenues and profitability given the competitive and structural environment, we continue to focus our business strategy on the following:

Targeted recruiting of primary care physicians and physicians in key specialties; Retention of physicians and efforts to improve physician satisfaction;

Retention and, where needed, recruitment of non-physician employees involved in patient care and efforts to improve employee satisfaction;

Measurement and improvement of quality of patient care and perceptions of such quality in communities where our hospitals are located;

22

Business Strategy 47

Targeted investments in new technologies, new service lines and capital improvements at our facilities;

Improvements in management of expenses and revenue cycle;

Negotiation of improved reimbursement rates with non-governmental payors; and

Strategic growth through acquisition and integration of hospitals and other healthcare facilities where valuations are attractive and we can identify opportunities for improved financial performance through our management or ownership.

Regulatory Environment

Our business and our hospitals are highly regulated, and the penalties for noncompliance are severe. We are required to comply with extensive, extremely complicated and overlapping government laws and regulations at the federal, state and local levels. These laws and regulations govern every aspect of how our hospitals conduct their operations, from what service lines must be offered in order to be licensed as an acute care hospital, to whether our hospitals may employ physicians, and to how (and whether) our hospitals may receive payments pursuant to the Medicare and Medicaid programs. The failure to comply with these laws and regulations can result in severe penalties including criminal penalties, civil sanctions, and the loss of our ability to receive reimbursements through the Medicare and Medicaid programs.

Not only are our hospitals heavily regulated, but the rules, regulations and laws to which they are subject often change, with little or no notice, and are often interpreted and applied differently by various regulatory agencies with authority to enforce such requirements. Each change or conflicting interpretation may require our hospitals to make changes in their facilities, equipment, personnel or services, and may also require that standard operating policies and procedures be re-written and re-implemented. The cost of complying with such laws and regulations is a significant component of our overall expenses. Further, this expense has grown in recent periods because of new regulatory requirements and the severity of the penalties associated with non-compliance. Management believes compliance expenses will continue to grow in the foreseeable future.

Health Care Reform

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 (collectively, the Affordable Care Act) were signed into law on March 23, 2010 and March 30, 2010, respectively. The Affordable Care Act dramatically alters the United States healthcare system and is intended to decrease the number of uninsured Americans and reduce the overall cost of healthcare. The Affordable Care Act attempts to achieve these goals by, among other things, requiring most Americans to obtain health insurance, expanding Medicare and Medicaid eligibility, reducing Medicare and Medicaid payments, including disproportionate share hospital (DSH) payments, expanding the Medicare program s use of value-based purchasing programs, tying hospital payments to the satisfaction of certain quality criteria, bundling payments to hospitals and other providers, and instituting certain private health insurance reforms. Although a majority of the measures contained in the Affordable Care Act do not take effect until 2013, certain of the reductions in Medicare spending, such as negative adjustments to the Medicare hospital inpatient and outpatient prospective payment system market basket updates and the incorporation of productivity adjustments to the Medicare program s annual inflation updates, became effective in 2010 or will be implemented in 2011 and 2012. In addition, there have been a number of challenges to the Affordable Care Act, and some courts have ruled that the requirement for individuals to carry health insurance or the Affordable Care Act in its entirety is unconstitutional. Several bills have been and will likely continue to be introduced in Congress to deny funding for, repeal or amend all or significant provisions of the Affordable Care Act. It is difficult to predict the full impact of the Affordable Care Act due to its complexity, lack of implementing regulations and interpretive guidance, gradual and potentially delayed implementation, pending court challenges, and possible repeal and/or amendment, as well as our inability to foresee how individuals and businesses will respond to the choices afforded them by the

Affordable Care Act. As a result, it is difficult to predict the full impact that the Affordable Care Act will have on our revenue and results of operations.

On March 31, 2011, the Centers for Medicare and Medicaid Services (CMS) issued proposed regulations under the Affordable Care Act that are intended to allow physicians, hospitals, and other health care providers to coordinate care for Medicare beneficiaries through Accountable Care Organizations

23

Health Care Reform 49

(ACOs). ACOs are new health care entities that were created by the Affordable Care Act in an effort to create incentives for health care providers to work together to treat a patient across different care settings. The ACO program is intended to produce savings as a result of improved quality and operational efficiency. The proposed rules outline certain key characteristics of an ACO, including the scope and length of an ACO s contract with CMS, the required governance of an ACO, the assignment of Medicare beneficiaries to an ACO, the payment models under which an ACO can share in cost savings, and the quality and other reporting requirements expected of an ACO. Under the proposed regulations, patient and provider participation in ACOs will be voluntary. We will continue to monitor developments in the proposed ACO regulations. We cannot predict if the proposed ACO rules will be adopted or, if adopted, if they will be adopted in their current form.

Medicare and Medicaid Reimbursement

Medicare payment methodologies have been, and can be expected to continue to be, significantly revised based on cost containment and policy considerations. CMS has already begun to implement some of the Medicare reimbursement reductions required by the Affordable Care Act. These revisions will likely be more frequent and significant as more of the Affordable Care Act s changes and cost-saving measures become effective.

On April 19, 2011, CMS issued its hospital inpatient prospective payment system (IPPS) proposed rule for federal fiscal year (FFY) 2012, which begins on October 1, 2011. Among other things, the proposed rule would provide for a market basket increase of 1.5% for hospitals that successfully report the quality measures for the Hospital Inpatient Quality Reporting (IQR) Program (formerly the Reporting Hospital Quality Data for Annual Payment Update Program) in FFY 2012 and -0.5% for those that do not. The update is based on a projected inflation increase of 2.8% in hospital costs, which is reduced by a multi-factor productivity adjustment of 1.2% and an additional 0.1% as required by the Affordable Care Act. Under the proposed rule, Medicare payments would also be increased by 1.1% in response to the outcome of litigation regarding the Medicare program s rural floor budget neutrality adjustments for FY 2007 and FY 2008 and reduced by 3.15%, as required by Transitional Medical Assistance, Abstinence Education, and Qualifying Individuals Programs Extension Act of 2007 (the TMA Act). CMS has indicated that an additional -0.75% adjustment will be required in the future to recover the remaining amounts that are required to be recouped under the TMA Act. In addition, the proposed rule also expands the quality measures that hospitals must report in FFYs 2014 and 2015 to avoid a 2% payment reduction under the IQR Program and adds one new condition to the list of hospital-acquired conditions (HACs) for the purposes of Medicare s HAC policy, which prevents hospitals from being paid at a higher rate for treating a beneficiary if the sole reason for the higher payment is the occurrence, during the beneficiary s hospital stay, of one of the conditions on the HAC list. CMS projects that, under the proposed rule, Medicare reimbursement for hospital inpatient services will decrease by 0.5% between FFY 2011 and FFY 2012.

In addition, many of the states in which we operate are facing budgetary challenges and have adopted, or may be considering, legislation that is intended to reduce Medicaid coverage and program eligibility, enroll Medicaid recipients in managed care programs, and/or impose additional taxes on hospitals to help finance or expand their Medicaid programs. Such budget cuts, federal or state legislation, or other changes in the administration or interpretation of government health programs by government agencies or contracted managed care organizations could have a material adverse effect on our financial position and results of operations. Congress has made an effort to address the financial challenges Medicaid is facing by recently increasing the amount of Medicaid funding available to states through the American Recovery and Reinvestment Act of 2009 (ARRA) and the Education, Jobs, and Medicaid Assistance Act (the Assistance Act), which increased Federal Medical Assistance Percentage (FMAP) payments through June 30, 2011. We cannot predict if the increased FMAP payments will be further extended or the impact that the phase-out of the increased FMAP payments will have on state Medicaid programs in the future.

Medicare and Medicaid spending continues to be a key issue in the ongoing Congressional budget debates. Both the President and Congress have proposed revisions to the Medicare and Medicaid programs that could have a substantial impact on the reimbursement that is paid to providers. We cannot predict whether Congress will make substantial changes to the Medicare and/or Medicaid programs and, if so, how any such changes would impact our revenue and results of operations.

24

Adoption of Electronic Health Records

The Health Information Technology for Economic and Clinical Health Act (HITECH Act) was enacted into law on February 17, 2009 as part of ARRA. The HITECH Act includes provisions designed to increase the use of electronic health records (EHR) by both physicians and hospitals. We intend to comply with the EHR meaningful use requirements of the HITECH Act in time to qualify for the maximum available Medicare and Medicaid incentive payments. Our compliance will result in significant costs including professional services focused on successfully designing and implementing our EHR solutions along with costs associated with the hardware and software components of the project. We continue to refine our budgeted costs and the expected reimbursement improvements associated with our EHR initiatives and have the potential to receive reimbursement in the later part of 2011. We currently estimate that at a minimum total costs incurred to comply will be recovered through improved reimbursement amounts over the projected lifecycle of this initiative.

Privacy and Security Regulations

The HITECH Act also contains a number of provisions that significantly expand the reach of the Health Insurance Portability and Accountability Act (HIPAA). For example, the HITECH Act imposes varying civil monetary penalties and creates a private cause of action for state attorneys general for certain HIPAA violations, extends HIPAA security provisions to business associates, and creates new security breach notification requirements.

These changes will require substantial operational changes for HIPAA covered entities and their business associates. Among other things, the proposed regulations would provide for new requirements for business associate agreements and a transition period for compliance, set new limits on the use and disclosure of health information for marketing and fundraising, prohibit the sale of patient health information without patient authorization, enhance individuals rights to obtain electronic copies of their medical records and restrict the disclosure of certain information, add new requirements for notices of privacy practices, modify restrictions on authorizations for the use of health information for research, and implement new changes to the HIPAA enforcement regulations.

Compliance with these new and proposed standards and the overlapping state laws regarding the protection of personal information requires significant commitment and action by our facilities, and we may incur significant costs in implementing the policies and systems required to comply.

Revenue Sources

Our hospitals generate revenues by providing healthcare services to our patients. Depending upon the patient s medical insurance coverage, we are paid for these services by governmental Medicare and Medicaid programs, commercial insurance, including managed care organizations, and directly by the patient. The amounts we are paid for providing healthcare services to our patients vary depending upon the payor. Governmental payors generally pay significantly less than the hospital s customary charges for the services provided. Insured patients are generally not responsible for any difference between customary hospital charges and the amounts received from commercial insurance payors. However, insured patients are responsible for payments not covered by insurance, such as exclusions, deductibles and co-payments.

Revenues from governmental payors, such as Medicare and Medicaid, are controlled by complex rules and regulations that stipulate the amount a hospital is paid for providing healthcare services. We must comply with these rules and regulations to continue to be eligible to participate in the Medicare and Medicaid programs. These rules and regulations are subject to frequent changes as a result of legislative and administrative action and annual payment

adjustments on both the federal and the state levels. These changes will likely become more frequent and significant as the healthcare reform provisions of the Affordable Care Act are implemented.

Revenues from HMOs, PPOs and other private insurers are subject to contracts and other arrangements that require us to discount the amounts we customarily charge for healthcare services. These discounted arrangements often limit our ability to increase charges in response to increasing costs. We actively negotiate with these payors in an effort to maintain or increase the pricing of our healthcare services.

25

Revenue Sources 53

Self-pay revenues are primarily generated through the treatment of uninsured patients. Our hospitals have experienced an increase in self-pay revenues during recent years as well as during the first quarter of 2011 as a result of a combination of broad economic factors, including high levels of unemployment in many of our markets, reductions in state Medicaid budgets and increasing numbers of individuals and employers who choose not to purchase insurance.

Increasing self-pay revenue further results in increases to our provision for doubtful accounts.

In recent periods, our business has experienced a shift in revenue from inpatient admissions to outpatient procedures.

This trend has occurred due to a variety of factors including our strategic focus on improving our emergency departments and diagnostic lines of business. In addition, our hospitals, like those of other hospital companies, have experienced a shift from inpatient admissions to outpatient observations for a portion of our patient population. We believe the reasons for this shift, include, but are not limited to, the continuing competition from various providers and utilization pressure by both governmental programs and commercial insurance payors.

Results of Operations

The following definitions apply throughout the remaining portion of *Management s Discussion and Analysis of Financial Condition and Results of Operations:*

Admissions. Represents the total number of patients admitted (in the facility for a period in excess of 23 hours) to our hospitals and used by management and investors as a general measure of inpatient volume.

bps. Basis point change.

Continuing operations. Continuing operations information includes the results of our same-hospital operations but excludes the results of our hospitals that have previously been disposed.

Effective tax rate. Provision for income taxes as a percentage of income from continuing operations before income taxes less net income attributable to noncontrolling interests.

Emergency room visits. Represents the total number of hospital-based emergency room visits.

Equivalent admissions. Management and investors use equivalent admissions as a general measure of combined inpatient and outpatient volume. We compute equivalent admissions by multiplying admissions (inpatient volume) by the outpatient factor (the sum of gross inpatient revenue and gross outpatient revenue and then dividing the resulting amount by gross inpatient revenue). The equivalent admissions computation equates outpatient revenue to the volume measure (admissions) used to measure inpatient volume resulting in a general measure of combined inpatient and outpatient volume.

Medicare case mix index. Refers to the acuity or severity of illness of an average Medicare patient at our hospitals.

N/A. Not applicable.

Net revenue days outstanding. We compute net revenue days outstanding by dividing our accounts receivable net of allowance for doubtful accounts, by our revenue per day. Our revenue per day is calculated by dividing our quarterly revenues, including revenues for held for sale / disposed of hospitals, by the number of calendar days in the quarter.

Outpatient surgeries. Outpatient surgeries are those surgeries that do not require admission to our hospitals.

Results of Operations 54

Same-hospital. Same-hospital information includes the results of our corporate office and the same 47 hospitals operated during the three months ended March 31, 2011 and 2010. Same-hospital information excludes the results of HighPoint Health Systems (HighPoint) which we acquired effective September 1, 2010, Clark Regional Medical Center (Clark), which we acquired effective May 1, 2010, and our hospitals that have previously been disposed.

26

Results of Operations 55

Operating Results Summary

The following table presents summaries of results of operations for the three months ended March 31, 2011 and 2010 (dollars in millions):

	Three Months Ended March 31,						
	2011						
	Amount	% of Revenues	Amount	% of Revenues			
Revenues	\$888.6	100.0 %	\$786.2	100.0 %			
Salaries and benefits	334.4	37.6	303.3	38.6			
Supplies	118.7	13.4	108.4	13.8			
Other operating expenses	161.6	18.2	140.4	17.8			
Provision for doubtful accounts	130.1	14.6	102.1	13.0			
Depreciation and amortization	39.7	4.5	36.1	4.6			
Interest expense, net	29.2	3.3	25.1	3.2			
•	813.7	91.6	715.4	91.0			
Income from continuing operations before income taxes	74.9	8.4	70.8	9.0			
Provision for income taxes	28.4	3.2	26.6	3.4			
Income from continuing operations	46.5	5.2	44.2	5.6			
Less: Net income attributable to noncontrolling interests	(0.7)	(0.1)	(0.9)	(0.1)			
Income from continuing operations attributable to LifePoint Hospitals, Inc.	\$45.8	5.1 %	\$43.3	5.5 %			

Revenues

The following table shows our revenues and the key drivers of our revenues for the three months ended March 31, 2011 and 2010:

	Three Mont March 31, 2011	ths Ended 2010	Increase (Decrease)	% Increase (Decrease)	
Continuing operations:					
Revenues (dollars in millions)	\$ 888.6	\$ 786.2	\$ 102.4	13.0 %	
Admissions	51,716	49,292	2,424	4.9	
Equivalent admissions	107,931	100,704	7,227	7.2	
Revenues per equivalent admission	\$ 8,233	\$ 7,807	\$ 426	5.5	
Medicare case mix index	1.30	1.32	(0.02)	(1.5)	
Average length of stay (days)	4.4	4.4			
Inpatient surgeries	13,360	13,542	(182)	(1.3)	
Outpatient surgeries	38,905	36,956	1,949	5.3	
Emergency room visits	254,770	222,032	32,738	14.7	
Outpatient factor	2.09	2.04	0.05	2.5	
Same-hospital:					

Edgar Filing: LIFEPOINT HOSPITALS, INC. - Form 10-Q

Revenues (dollars in millions) Admissions Equivalent admissions	\$ 831.8 48,690 100,837	\$ 786.2 49,292 100,704	\$ 45.6 (602 133)	5.8 (1.2 0.1	%)
Revenues per equivalent admission	\$ 8,249	\$ 7,807	\$ 442		5.7	
Medicare case mix index	1.30	1.32	(0.02)	(1.5)
Average length of stay (days)	4.4	4.4				
Inpatient surgeries	12,641	13,542	(901)	(6.7)
Outpatient surgeries	36,946	36,956	(10)		
Emergency room visits	237,441	222,032	15,409		6.9	
Outpatient factor	2.07	2.04	0.03		1.5	

27

Revenues 57

The following table shows the sources of our revenues by payor for the three months ended March 31, 2011 and 2010, expressed as a percentage of total revenues, including adjustments to estimated reimbursement amounts:

	Continuing	Continuing Operations Same-Hospital			
	2011	2010	2011	2010	
Medicare	30.9 %	31.5 %	31.0 %	31.5	%
Medicaid	12.0	11.8	11.8	11.8	
HMOs, PPOs and other private insurers	40.3	41.7	40.5	41.7	
Self-Pay	15.9	13.9	15.8	13.9	
Other	0.9	1.1	0.9	1.1	
	100.0 %	100.0 %	100.0 %	100.0	%

For the three months ended March 31, 2011, our revenues increased by \$45.6 million, or 5.8%, to \$831.8 million on a same-hospital basis as compared to \$786.2 million for the same period last year. This primarily resulted from increases in self-pay, Medicare and HMO, PPOs and other private insurers revenues. Same-hospital self-pay revenues, inclusive of both inpatient and outpatient services, increased by \$22.5 million as compared to the same period last year. These increases were largely driven by higher emergency room visits from our self-pay population, overall high levels of unemployment in the majority of our communities and pricing increases. The increase in our self-pay revenues resulted in an increase in our provision for doubtful accounts, as further discussed in our analysis of our provision for doubtful accounts. Additionally, Medicaid revenues increased as a result of the receipt of approximately \$6.7 million in additional disproportionate share payments and access payments at certain hospitals based on our participation in state provider programs. Our participation in these state provider programs resulted in increases to our non-income taxes expense, as further discussed in our analysis of our other operating expenses. As a result, our revenues per equivalent admission increased by 5.7% to \$8,249 on a same-hospital basis as compared to \$7,807 for the same period last year.

Certain changes have been made to our historical sources of revenues table above. Specifically, we previously classified our revenues related to our owned physician practices as other revenue. In 2010 and for all previously reported periods, we changed the classification of our revenues for our owned physician practices from other to the respective payor classifications, as appropriate. These reclassifications reduced other revenue as a percentage of total revenues and increased Medicare, Medicaid, HMOs, PPOs and other private insurers and self-pay as a percentage of total revenues. We have determined that it is more appropriate to classify our owned physician practices revenue by their respective payor classification.

Expenses

Salaries and Benefits

The following table summarizes our salaries and benefits, man-hours per equivalent admission and salaries and benefits per equivalent admission for the three months ended March 31, 2011 and 2010:

	Three Months Ended March 31,					
	2011	% of Revenues	2010	% of Revenues	Increase	% Increase
Continuing operations:						
Salaries and benefits (dollars in millions)	\$334.4	37.6 %	\$303.3	38.6 %	\$ 31.1	10.2 %

Expenses 58

Edgar Filing: LIFEPOINT HOSPITALS, INC. - Form 10-Q

Man-hours per equivalent admission	96.5	N/A	93.0	N/A	3.5	3.8	%
Salaries and benefits per equivalent admission	\$3,099	N/A	\$3,022	N/A	\$ 77	2.6	%
Same-hospital:							
Salaries and benefits (dollars in millions)	\$310.5	37.3 %	\$ 303.3	38.6 %	\$ 7.2	2.4	%
Man-hours per equivalent admission	95.3	N/A	93.0	N/A	2.3	2.6	%
Salaries and benefits per equivalent admission	\$3,081	N/A	\$3,022	N/A	\$ 59	2.0	%

28

Salaries and Benefits 59

For the three months ended March 31, 2011, our salaries and benefits expense increased to \$310.5 million, or 2.4%, on a same-hospital basis as compared to \$303.3 million for the same period last year. This increase in our same-hospital salaries and benefits expense is primarily a result of the impact of compensation increases for our employees and a slight increase in man-hours per equivalent admission to 95.3, or 2.6%, on a same-hospital basis as compared to 93.0 for the same period last year. These increases were partially offset by lower employee benefits cost, primarily medical benefits expense.

Supplies

The following table summarizes our supplies and supplies per equivalent admission for the three months ended March 31, 2011 and 2010:

Three Months Ended March 31,				%		
	2011	% of Revenues	2010	% of Revenues	Increase	Increase
Continuing operations:						
Supplies (dollars in millions)	\$118.7	13.4 %	\$ 108.4	13.8 %	\$ 10.3	9.5 %
Supplies per equivalent admission	\$1,100	N/A	\$ 1,077	N/A	\$ 23	2.2 %
Same-hospital:						
Supplies (dollars in millions)	\$111.8	13.4 %	\$ 108.4	13.8 %	\$ 3.4	3.1 %
Supplies per equivalent admission	\$1,109	N/A	\$ 1,077	N/A	\$ 32	3.0 %

For the three months ended March 31, 2011, our supplies expense increased to \$111.8 million, or 3.1% on a same-hospital basis as compared to \$108.4 million for the same period last year. This increase in our same-hospital supplies expense for the three months ended March 31, 2011 was primarily a result of an increase in our supplies expense per equivalent admission to \$1,109, or 3.0%, as compared to \$1,077 for the same period last year. Supplies per equivalent admission increased as a result of a higher utilization of more expensive supplies, predominantly cancer related supplies, as well as an increase in our pharmacy supplies expense.

Other Operating Expenses

The following table summarizes our other operating expenses for the three months ended March 31, 2011 and 2010 (dollars in millions):

	Three Months Ended March 31,				Increase	% Increase
	2011	% of Revenues	2010	% of Revenues	(Decrease)	,
Continuing operations:						
Professional fees	\$23.8	2.7 %	\$ 19.3	2.4 %	\$ 4.5	23.3 %
Utilities	13.9	1.6	12.6	1.6	1.3	10.1
Repairs and maintenance	19.0	2.1	17.0	2.2	2.0	11.8
Rents and leases	7.4	0.8	6.6	0.8	0.8	11.7
Insurance	9.9	1.1	12.0	1.5	(2.1)	(17.9)
Physician recruiting	6.6	0.7	6.0	0.8	0.6	11.2
Contract services	43.3	4.9	37.2	4.7	6.1	16.4
Non-income taxes	18.1	2.0	12.2	1.6	5.9	48.5
Other	19.6	2.3	17.5	2.2	2.1	12.2

Supplies 60

Edgar Filing: LIFEPOINT HOSPITALS, INC. - Form 10-Q

	\$161.6	18.2 %	\$ 140.4	17.8 %	\$ 21.2	15.1 %
Same-hospital:						
Professional fees	\$21.6	2.6 %	\$ 19.3	2.4 %	\$ 2.3	11.8 %
Utilities	12.8	1.5	12.6	1.6	0.2	1.4
Repairs and maintenance	17.5	2.1	17.0	2.2	0.5	3.1
Rents and leases	6.7	0.8	6.6	0.8	0.1	1.1
Insurance	9.5	1.1	12.0	1.5	(2.5)	(21.0)
Physician recruiting	6.5	0.8	6.0	0.8	0.5	8.4
Contract services	40.7	4.9	37.2	4.7	3.5	9.3
Non-income taxes	16.5	2.0	12.2	1.6	4.3	35.0
Other	18.8	2.4	17.5	2.2	1.3	8.0
	\$150.6	18.2 %	\$ 140.4	17.8 %	\$ 10.2	7.3 %

29

For the three months ended March 31, 2011, our other operating expenses increased to \$150.6 million, or 7.3% on a same-hospital basis as compared to \$140.4 million for the same period last year. This increase for the three months ended March 31, 2011 was primarily a result of increases in professional fees, contract services and non-income taxes, partially offset by a decrease in insurance expense.

As a shortage of physicians continues to become more acute, we have experienced increasing professional fees in areas such as emergency room physician coverage and hospitalists. We expect this trend to continue and that professional fees as a percentage of revenues will increase in future periods.

On a same-hospital basis, our contract services expense increased primarily as a result of increased accounts receivable collection fees and fees related to our conversion of the clinical and patient accounting information system applications at certain hospitals. Finally, our non-income taxes increased primarily as a result of increases in state provider taxes and property taxes experienced at certain hospitals in various states.

These increases were partially offset by a decrease in our insurance expense. Our insurance expense decreased compared to the same period last year primarily because of favorable claim development for our professional and general liability claims experienced during the current period.

Provision for Doubtful Accounts

The following table summarizes our provision for doubtful accounts and related key indicators for the three months ended March 31, 2011 and 2010 (dollars in millions):

	Three M	Three Months Ended March 31,				%
	2011	% of Revenue:	s 2010	% of Revenues	Increase	
Continuing operations:						
Provision for doubtful accounts	\$130.1	14.6 %	\$ 102.1	13.0 %	\$ 28.0	27.5 %
Related key indicators:						
Charity care write-offs	\$19.7	2.2 %	\$13.9	1.8 %	\$ 5.8	41.4 %
Self-pay revenues, net of charity care write-offs and uninsured discounts	\$141.2	15.9 %	\$ 109.1	13.9 %	\$ 32.1	29.4 %
Net revenue days outstanding (at end of period)	40.5	N/A	40.0	N/A	0.5	1.3 %
Same-hospital:						
Provision for doubtful accounts	\$120.2	14.4 %	\$ 102.1	13.0 %	\$ 18.1	17.7 %
Related key indicators:						
Charity care write-offs	\$17.1	2.1 %	\$13.9	1.8 %	\$ 3.2	23.1 %
Self-pay revenues, net of charity care write-offs and uninsured discounts	\$131.6	15.8 %	\$ 109.1	13.9 %	\$ 22.5	20.6 %
Net revenue days outstanding (at end of period)	40.3	N/A	40.0	N/A	0.3	0.8 %

For the three months ended March 31, 2011, our provision for doubtful accounts increased by \$28.0 million, or 27.5%, to \$130.1 million on a continuing operations basis and by \$18.1 million, or 17.7%, to \$120.2 million on a same-hospital basis as compared to the same period last year. This increase was primarily the result of increases in self-pay revenues during the three months ended March 31, 2011 as compared to the same period last year. Same-hospital self-pay revenues increased by \$22.5 million over the same period last year and represented 15.8% of

revenues, as compared to 13.9% of revenues in the same period last year. Self-pay revenues continued to increase for both our inpatient and outpatient services, including outpatient emergency room visits, which were primarily driven by high levels of unemployment in the majority of our communities and pricing increases. These increases were partially offset by an increase in up-front cash collections for the three months ended March 31, 2011, as compared to the same period last year. The provision and allowance for doubtful accounts are critical accounting estimates and are further

30

discussed in Part II, Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations, Critical Accounting Estimates, in our 2010 Annual Report on Form 10-K.

Depreciation and Amortization

For the three months ended March 31, 2011, our depreciation and amortization expense increased to \$39.7 million, or 9.8%, on a continuing operations basis as compared to \$36.1 million for the same period last year. Our depreciation and amortization expense increased as a result of our recent acquisitions of HighPoint and Clark, capital improvement projects completed during 2010 and the first quarter of 2011. During the first quarter of 2011, we have experienced a significant increase in our spending related to information systems as the result of various initiatives and requirements, including compliance with the HITECH Act. We anticipate increasing our spending related to information systems throughout 2011 as compared to 2010 and prior years. As a result, we anticipate that our depreciation and amortization expense as a percentage of revenues will increase in future periods.

Interest Expense

Our interest expense increased by \$4.1 million, or 16.2%, to \$29.2 million, for the three months ended March 31, 2011, as compared to \$25.1 million for the same period last year. This increase in interest expense was largely attributable to an increase in our outstanding debt balance, excluding unamortized discounts of convertible debt instruments, to \$1,651.3 million at March 31, 2011 as compared to \$1,501.9 million at March 31, 2010 and increases in our applicable annual interest rates. Effective September 23, 2010, we issued \$400.0 million of 6.625% unsecured senior notes due October 1, 2020 (the 6.625% Senior Notes) in a private placement. The net proceeds from this issuance were used to repay \$249.2 million of our outstanding borrowings under our Term B Loans and \$6.0 million of our outstanding borrowings under our Province 7½% senior subordinated notes due 2013 (the Province 7½% Notes). Interest on the 6.625% Senior Notes is payable at an annual fixed rate of 6.625% as compared to a variable rate under our Term B Loans, which for the three months ended March 31, 2011, on a weighted average basis, was 3.09%. These increases were partially offset by declines in interest expense attributable to our interest rate swap agreement. On November 30, 2010, the notional amount of our interest rate swap decreased from \$450.0 million to \$300.0 million. As the notional amount of our interest rate swap has continued to decline, a larger portion of our total outstanding debt has become subject to floating interest rates that are lower than our fixed rate under the agreement of 5.585% for the three months ended March 31, 2011 as compared to the same period last year. For a further discussion of our debt and corresponding interest rates, see Liquidity and Capital Resources Debt.

Provision for Income Taxes

Our provision for income taxes was \$28.4 million, or 3.2% of revenues, for the three months ended March 31, 2011, as compared to \$26.6 million, or 3.4% of revenues, for the same period last year. The effective tax rate increased slightly to 38.3% for the three months ended March 31, 2011, as compared to 38.0% for the same period last year.

Liquidity and Capital Resources

Liquidity

Our primary sources of liquidity are cash flows provided by our operations and our debt borrowings. We believe that our internally generated cash flows and the amounts available under our debt agreements will be adequate to service existing debt, finance internal growth and fund capital expenditures and certain small to mid-size hospital acquisitions.

Liquidity 65

TABLE OF CONTENTS

The following table presents summarized cash flow information for the three months ended March 31, 2011 and 2010 (in millions):

	Three M	onths Ende	ed
	March 3	1,	
	2011	2010	
Net cash provided by operating activities continuing operations	\$115.8	\$ 83.5	
Less: Purchase of property and equipment	(55.9)	(34.0)
Free operating cash flow	59.9	49.5	
Acquisitions, net of cash acquired	(1.7)	(16.9)
Proceeds from exercise of stock options	17.5	9.2	
Proceeds from employee stock purchase plans	0.7	0.6	
Repurchases of common stock	(5.5)	(9.0)
Payment of debt refinance costs		(4.4)
Distributions to noncontrolling interests	(1.0)	(0.5)
Proceeds from redeemable noncontrolling interests		4.2	
Other	(1.3)	(0.3)
Cash flows from operations provided by (used in) discontinued operations	0.2	(0.2)
Net increase in cash and cash equivalents	\$68.8	\$ 32.2	

The non-GAAP metric of free operating cash flow is an important liquidity measure for us. Our computation of free operating cash flow consists of net cash flows provided by continuing operations less cash flows used for the purchase of property and equipment.

Our cash flows provided by continuing operations for the three months ended March 31, 2011 were positively impacted as we collected government based accounts receivable balances that had previously built up due to provider number matters at our recently acquired HighPoint and Clark hospitals, an increase in up-front collections as well the timing and amount of cash payments for miscellaneous expenses and interest as compared same period last year.

We believe that free operating cash flow is useful to investors and management as a measure of the ability of our business to generate cash and to repay and incur additional debt. Computations of free operating cash flow may differ from company to company. Therefore, free operating cash flow should be used as a complement to, and in conjunction with, our condensed consolidated statements of cash flows presented in our condensed consolidated financial statements included elsewhere in this report.

Capital Expenditures

We have made significant, targeted investments at our hospitals to add new technologies, modernize facilities and expand the services available. These investments should assist in our efforts to attract and retain physicians, to offset outmigration of patients and to make our hospitals more desirable to our employees and potential patients.

The following table reflects our capital expenditures for the three months ended March 31, 2011 and 2010 (dollars in millions):

Three Months Ended March 31,

Capital Expenditures 66

Edgar Filing: LIFEPOINT HOSPITALS, INC. - Form 10-Q

	2011	2010
Capital projects	\$ 19.6	\$ 18.3
Routine	17.7	7.4
Information systems	18.6	8.3
	\$ 55.9	\$ 34.0
Depreciation expense	\$ 39.0	\$ 35.6
Ratio of capital expenditures to depreciation expense	143.3 %	95.5 %

32

Capital Expenditures 67

We have a formal and intensive review procedure for the authorization of capital expenditures. The most important financial measure of acceptability for a discretionary capital project is whether its projected discounted cash flow return on investment exceeds our projected cost of capital for that project. We expect to continue to invest in information systems, modern technologies, emergency room and operating room expansions, the construction of medical office buildings for physician expansion and the reconfiguration of the flow of patient care. During the first quarter of 2011, we have experienced a significant increase in our spending related to information systems as the result of various initiatives and requirements, including compliance with the HITECH Act. We anticipate increasing our spending related to information systems throughout 2011 as compared to 2010 and prior years.

Debt

An analysis and roll-forward of our long-term debt during the first quarter of 2011 is as follows (in millions):

				Amortiza	tion
	December	Payments	Proceed	lsof	March 31,
	31,	of	from	Convertib	
	2010	Borrowing	g&orrow:	in De bt	2011
				Discounts	S
Senior Secured Credit Agreement:					
Term B Loans	\$443.7	\$	\$	\$	\$443.7
Revolving Loans					
Province 7½% Senior Subordinated Notes	0.1				0.1
6.625% Senior Notes	400.0				400.0
3½% Notes	575.0				575.0
31/4% Debentures	225.0				225.0
Unamortized discounts on 31/4% Debentures and	(70.9			5 0	(72.0
3½% Notes	(79.8)			5.9	(73.9)
Capital leases	7.9	(0.4)			7.5
-	\$1,571.9	\$ (0.4)	\$	\$ 5.9	\$1,577.4

We use leverage, or our total debt to total capitalization ratio, to make financing decisions. The following table illustrates our financial statement leverage and the classification of our debt at March 31, 2011 and December 31, 2010 (dollars in millions):

	March 31, 2011	December 31, 2010	Increase (Decrease)
Current portion of long-term debt	\$1.3	\$1.4	\$(0.1)
Long-term debt	1,576.1	1,570.5	5.6
Unamortized discounts of convertible debt instruments	73.9	79.8	(5.9)
Total debt, excluding unamortized discounts of convertible debt instruments	1,651.3	1,651.7	(0.4)
Total LifePoint Hospitals, Inc. stockholders equity	1,957.1	1,887.5	69.6
Total capitalization	\$3,608.4	\$3,539.2	\$69.2
Total debt to total capitalization	45.8 %	46.7 %	(90)bps
Percentage of:			

Debt 68

Edgar Filing: LIFEPOINT HOSPITALS, INC. - Form 10-Q

Fixed rate debt, excluding unamortized discounts of convertible debt instruments	73.1	%	73.1	%
Variable rate debt ^(a)	26.9 100.0	%	26.9 100.0	%
Percentage of: Senior debt	51.5	%	51.6	%
Subordinated debt, excluding unamortized discounts of convertible debt instruments	48.5		48.4	
	100.0	%	100.0	%

The above calculation does not consider the effect of our interest rate swap. Our interest rate swap mitigates a (a) portion of our floating rate risk on our outstanding variable rate borrowings which converts our variable rate debt to an annual fixed rate of 5.585%. Our interest rate swap decreases our variable

33

Debt 69

rate debt as a percentage of our outstanding debt from 26.9% to 8.7% as of March 31, 2011 and December 31, 2010. Please refer to Note 5 to our accompanying condensed consolidated financial statements included elsewhere in this report for a discussion of our interest rate swap agreement.

Capital Resources

Credit Agreement

Terms

Our credit agreement with Citicorp North America, Inc., as administrative agent and the lenders time to time party thereto, Bank of America, N.A., CIBC World Markets Corp., SunTrust Bank and UBS Securities LLC, as co-syndication agents and Citigroup Global Markets Inc. as sole lead arranger and sole book runner, as amended (the Credit Agreement), provides for term B loans (the Term B Loans), term A loans (the Term A Loans) and revolving loans (the Revolving Loans). The maturity date of our Term B Loans is contingent upon the refinancing of our outstanding 3½% convertible senior subordinated notes due May 15, 2014 (the 3½% Notes) beyond their current maturity date of May 15, 2014. Assuming that we refinance our outstanding 3½% Notes beyond their current maturity date, our Term B Loans will mature on April 15, 2015. If we do not refinance our outstanding 3½% Notes at least 91 days prior to their current maturity date our Term B Loans will mature on February 13, 2014. Additionally, our Term B Loans are subject to additional mandatory prepayments with a certain percentage of excess cash flow, as well as upon the occurrence of certain other events, as specifically described in our Credit Agreement. Our Term A Loans and our Revolving Loans components mature on December 15, 2012. Our Credit Agreement is guaranteed on a senior secured basis by our subsidiaries with certain limited exceptions.

Letters of Credit and Availability

Our Credit Agreement provides for the issuance of letters of credit up to \$75.0 million. As of March 31, 2011, we had \$31.1 million in letters of credit outstanding that were related to the self-insured retention level of our general and professional liability insurance and workers compensation programs as security for payment of claims. Issued letters of credit reduce the amounts available under our Revolving Loans. In accordance with the terms of our Credit Agreement, Revolving Loans available for borrowing were \$318.9 million as of March 31, 2011.

Our Credit Agreement contains uncommitted accordion features that permit us to borrow at a later date additional aggregate principal amounts of up to \$400.0 million of Term B Loans, \$250.0 million of Term A Loans and \$300.0 million of Revolving Loans, subject to obtaining additional lender commitments and the satisfaction of other conditions.

Interest Rates

Interest on the outstanding balance of the Term B Loans is payable at an adjusted LIBOR plus a margin of 2.750%. Interest on the Revolving Loans is payable at our option at either an adjusted base rate or an adjusted LIBOR plus a margin. The margin on Revolving Loans subject to an adjusted base rate ranges from 1.00% to 1.75%, based on our total leverage ratio. The margin on the Revolving Loans subject to an adjusted LIBOR ranges from 2.00% to 2.75% based on our total leverage ratio.

As of March 31, 2011, the applicable annual interest rate under the Term B Loans was 3.07%, which was based on the 90-day Adjusted LIBOR plus the applicable margins. The 90-day Adjusted LIBOR was 0.32% at March 31, 2011. The weighted-average applicable annual interest rate for the three months ended March 31, 2011 under the Term B

Capital Resources 70

Loans was 3.09%.

Covenants

Our Credit Agreement requires us to satisfy certain financial covenants, including a minimum interest coverage ratio and a maximum total leverage ratio. The interest coverage ratio can be no less than 3.50:1.00 and the total leverage ratio cannot exceed 3.75:1.00, both determined on a trailing four quarter basis. In addition, the Credit Agreement generally limits the amount we can spend on capital expenditures to no more than 10.0% of annual revenues. We were in compliance with these covenants as of March 31, 2011.

34

Interest Rates 71

In addition, our Credit Agreement contains customary affirmative and negative covenants, which among other things, limit our ability to incur additional debt, create liens, pay dividends, effect transactions with our affiliates, sell assets, pay subordinated debt, merge, consolidate, enter into acquisitions and effect sale leaseback transactions. It does not contain provisions that would accelerate the maturity dates upon a downgrade in our credit rating. However, a downgrade in our credit rating could adversely affect our ability to obtain other capital sources in the future and could increase our cost of borrowings.

6.625% Senior Notes

Our 6.625% unsecured senior notes with The Bank of New York Mellon Trust Company, N.A., as trustee, (the 6.625% Senior Notes) are due October 1, 2020 and bear interest at the rate of 6.625% per year, payable semi-annually on April 1 and October 1. The 6.625% Senior Notes are jointly and severally guaranteed on an unsecured senior basis by substantially all of our existing and future subsidiaries that guarantee our Credit Agreement.

We may redeem up to 35% of the aggregate principal amount of our 6.625% Senior Notes, at any time before October 1, 2013, with the net cash proceeds of one or more qualified equity offerings at a redemption price equal to 106.625% of the principal amount to be redeemed, plus accrued and unpaid interest, provided that at least 65% of the aggregate principal amount of its 6.625% Senior Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of any such qualified equity offering.

We may redeem our 6.625% Senior Notes, in whole or in part, at any time prior to October 1, 2015 at a price equal to 100% of the principal amount of the notes redeemed plus an applicable make-whole premium, plus accrued and unpaid interest, if any, to the date of redemption. We may redeem our 6.625% Senior Notes, in whole or in part, at any time on or after October 1, 2015, plus accrued and unpaid interest, if any, to the date of redemption plus a redemption price equal to a percentage of the principal amount of the notes redeemed based on the following redemption schedule:

October 1, 2015 to December 31, 2016	103.313 %
October 1, 2016 to December 31, 2017	102.208 %
October 1, 2017 to December 31, 2018	101.104 %
October 1, 2018 and thereafter	100.000 %

If we experience a change of control under certain circumstances, we must offer to repurchase all of the notes at a price equal to 101.000% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date.

The 6.625% Senior Notes contain customary affirmative and negative covenants, which among other things, limit our ability to incur additional debt, create liens, pay dividends, effect transactions with our affiliates, sell assets, pay subordinated debt, merge, consolidate, enter into acquisitions and effect sale leaseback transactions.

31/2% Notes

Our 3½% Notes bear interest at the rate of 3½% per year, payable semi-annually on May 15 and November 15. The 3½% Notes are convertible prior to March 15, 2014 under the following circumstances: (1) if the price of our common stock reaches a specified threshold during specified periods; (2) if the trading price of the 3½% Notes is below a specified threshold; or (3) upon the occurrence of specified corporate transactions or other events. On or after March 15, 2014, holders may convert their 3½% Notes at any time prior to the close of business on the scheduled trading day immediately preceding May 15, 2014, regardless of whether any of the foregoing circumstances has occurred.

Covenants 72

Subject to certain exceptions, we will deliver cash and shares of our common stock upon conversion of each \$1,000 principal amount of our 3½% Notes as follows: (i) an amount in cash, which we refer to as the principal return, equal to the sum of, for each of the 20 volume-weighted average price trading days during the conversion period, the lesser of the daily conversion value for such volume-weighted average price trading day and \$50; and (ii) a number of shares in an amount equal to the sum of, for each of the 20 volume-weighted average price trading days during the conversion period, any excess of the daily conversion

35

3½% Notes 73

TABLE OF CONTENTS

value above \$50. Our ability to pay the principal return in cash is subject to important limitations imposed by the Credit Agreement and the agreements or indentures governing any additional indebtedness that we incur in the future. If we do not make any payments we are obligated to make under the terms of the 3½% Notes, holders may declare an event of default.

The initial conversion rate is 19.3095 shares of our common stock per \$1,000 principal amount of the 3½% Notes (subject to certain events). This represents an initial conversion price of \$51.79 per share of the Company s common stock. In addition, if certain corporate transactions that constitute a change of control occur prior to maturity, we will increase the conversion rate in certain circumstances.

Upon the occurrence of a fundamental change (as specified in the indenture), each holder of the 3½% Notes may require us to purchase some or all of the 3½% Notes at a purchase price in cash equal to 100% of the principal amount of the 3½% Notes surrendered, plus any accrued and unpaid interest.

The indenture for the 3½% Notes does not contain any financial covenants or any restrictions on the payment of dividends, the incurrence of senior or secured debt or other indebtedness, or the issuance or repurchase of securities by us. The indenture contains no covenants or other provisions to protect holders of the 3½% Notes in the event of a highly leveraged transaction or other events that do not constitute a fundamental change.

31/4% Debentures

Our 3¼% Debentures bear interest at the rate of 3¼% per year, payable semi-annually on February 15 and August 15.

The 3¼% Debentures are convertible (subject to certain limitations imposed by the Credit Agreement) under the following circumstances: (1) if the price of our common stock reaches a specified threshold during the specified periods; (2) if the trading price of the 3¼% Debentures is below a specified threshold; (3) if the 3¼% Debentures have been called for redemption; or (4) if specified corporate transactions or other specified events occur. Subject to certain exceptions, we will deliver cash and shares of our common stock, as follows: (i) an amount in cash, which we refer to as the principal return, equal to the lesser of (a) the principal amount of the 3¼% Debentures surrendered for conversion and (b) the product of the conversion rate and the average price of our common stock, as set forth in the indenture governing the securities, which we refer to as the conversion value; and (ii) if the conversion value is greater than the principal return, an amount in shares of our common stock. Our ability to pay the principal return in cash is subject to important limitations imposed by the Credit Agreement and the agreements or indentures governing any additional indebtedness that we incur in the future. Based on the terms of the Credit Agreement, in certain circumstances, even if any of the foregoing conditions to conversion have occurred, the 3¼% Debentures will not be convertible, and holders of the 3¼% Debentures will not be able to declare an event of default under the 3¼% Debentures.

The initial conversion rate for the 3¼% Debentures is 16.3345 shares of our common stock per \$1,000 principal amount of 3¼% Debentures (subject to adjustment in certain events). This is equivalent to a conversion price of \$61.22 per share of common stock. In addition, if certain corporate transactions that constitute a change of control occur on or prior to February 20, 2013, we will increase the conversion rate in certain circumstances, unless such transaction constitutes a public acquirer change of control and we elect to modify the conversion rate into public acquirer common stock.

On or after February 20, 2013, we may redeem for cash some or all of the 3¼% Debentures at any time at a price equal to 100% of the principal amount of the 3¼% Debentures to be purchased, plus any accrued and unpaid interest. Holders may require us to purchase for cash some or all of the 3¼% Debentures on February 15, 2013, February 15,

31/4% Debentures 74

2015 and February 15, 2020 or upon the occurrence of a fundamental change, at 100% of the principal amount of the 31/4% Debentures to be purchased, plus any accrued and unpaid interest.

The indenture for the 3¼% Debentures does not contain any financial covenants or any restrictions on the payment of dividends, the incurrence of senior or secured debt or other indebtedness, or the issuance or repurchase of securities by us. The indenture contains no covenants or other provisions to protect holders of the 3¼% Debentures in the event of a highly leveraged transaction or fundamental change.

36

31/4% Debentures 75

Interest Rate Swap

We have an interest rate swap agreement with Citibank, N.A. (Citibank) as counterparty that requires us to make quarterly fixed rate payments to Citibank calculated on a notional amount of \$300.0 million as of March 31, 2011 at an annual fixed rate of 5.585% while Citibank is obligated to make quarterly floating payments to us based on the three-month LIBOR on the same referenced notional amount. We have designated our interest rate swap as a cash flow hedge instrument, which is recorded in our condensed consolidated balance sheets at its fair value in accordance with ASC 815-10, Derivatives and Hedging (ASC 815-10), based on the amount at which it could be settled, which is referred to in ASC 815-10 as the exit price. The exit price is based upon observable market assumptions and appropriate valuation adjustments for credit risk. We have categorized our interest rate swap as Level 2 in the fair value hierarchy, which ASC 820-10, Fair Value Measurements and Disclosures defines as observable market-based inputs or unobservable inputs that are corroborated by market data. Please refer to Note 5 to our accompanying condensed consolidated financial statements included elsewhere in this report for a further discussion of our interest rate swap agreement.

Liquidity and Capital Resources Outlook

We expect to increase our level of spending for capital expenditures in 2011 as compared to 2010. We have large projects in process at a number of our facilities. We are reconfiguring some of our hospitals to more effectively accommodate patient services, permit additional patient volume and a greater variety of services, and implementing various information system initiatives in our efforts to comply with the HITECH Act. For the three months ended March 31, 2011, we spent \$18.6 million on information systems. We anticipate spending in excess of \$75.0 million on information systems in 2011. At March 31, 2011, we had uncompleted projects with an estimated additional cost to complete and equip of approximately \$144.5 million. We anticipate funding these expenditures through cash provided by operating activities, available cash and borrowings available under our Credit Agreement.

Our business strategy contemplates the selective acquisition of additional hospitals and other healthcare service providers, and we regularly review potential acquisitions. These acquisitions may, however, require additional financing. We regularly evaluate opportunities to sell additional equity or debt securities, obtain credit agreements from lenders or restructure our long-term debt or equity for strategic reasons or to further strengthen our financial position. The sale of additional equity or convertible debt securities could result in additional dilution to our stockholders.

We believe that cash generated from our operations and borrowings available under our Credit Agreement will be sufficient to meet our working capital needs, the purchase prices for any potential facility acquisitions, planned capital expenditures and other expected operating needs over the next twelve months and into the foreseeable future prior to the maturity dates of our outstanding debt.

Contractual Obligations

We have various contractual obligations, which are recorded as liabilities in our condensed consolidated financial statements. Other items, such as certain purchase commitments and other executory contracts, are not recognized as liabilities in our condensed consolidated financial statements but are required to be disclosed. For example, we are required to make certain minimum lease payments for the use of property under certain of our operating lease agreements. During the three months ended March 31, 2011, there were no material changes in our contractual obligations as presented in our 2010 Annual Report on Form 10-K.

Interest Rate Swap 76

Off-Balance Sheet Arrangements

We had standby letters of credit outstanding of \$31.1 million as of March 31, 2011, all of which relates to the self-insured retention levels of our professional and general liability insurance and workers compensation programs as security for the payment of claims.

37

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

it requires assumptions to be made that were uncertain at the time the estimate was made; and changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates include the following areas:

Revenue recognition/Allowance for contractual discounts;
Allowance for doubtful accounts and provision for doubtful accounts;
Goodwill impairment analysis;
Reserves for self-insurance claims;
Accounting for stock-based compensation; and
Accounting for income taxes.

Contingencies

Please refer to Note 8 to our accompanying condensed consolidated financial statements included elsewhere in this report for a discussion of our material financial contingencies, including:

Legal proceedings and general liability claims;
Physician commitments; and
Capital expenditure commitments.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rates

The following discussion relates to our exposure to market risk based on changes in interest rates:

Outstanding Debt

We have an interest rate swap to manage our exposure to changes in interest rates. The interest rate swap converts a portion of our indebtedness to a fixed rate with a notional amount of \$300.0 million at March 31, 2011 at an annual fixed rate of 5.585%. Accordingly, we are slightly exposed to market risk related to fluctuations in interest rates. The notional amount of the swap agreement represents a balance used to calculate the exchange of cash flows and is not an asset or liability. Any market risk or opportunity associated with this swap agreement is offset by the opposite market impact on the related debt. Our interest rate swap agreement exposes us to credit risk in the event of non-performance by Citibank. However, we do not anticipate non-performance by Citibank.

As of March 31, 2011, we had outstanding debt, excluding \$73.9 million of unamortized discounts on our convertible debt instruments, of \$1,651.3 million, 26.9%, or \$443.7 million, of which was subject to variable rates of interest. However, our interest rate swap decreases our variable rate debt as a percentage of our outstanding debt from 26.9%

to 8.7% as of March 31, 2011.

38

Outstanding Debt 79

Our Term B Loans, 6.625% Senior Notes, 3½% Notes and 3¼% Debentures are our long-term debt instruments with carrying amounts different from their fair value as of March 31, 2011 and December 31, 2010. The carrying amount and fair value of these instruments as of March 31, 2011 and December 31, 2010 were as follows (in millions):

	Carrying Amount		Fair Value	
	March	December	March	December
	31,	31,	31,	31,
	2011	2010	2011	2010
Term B Loans	\$443.7	\$ 443.7	\$445.4	\$ 445.4
6.625% Senior Notes	\$400.0	\$ 400.0	\$408.0	\$ 398.0
31/2% Notes, excluding unamortized discount	\$575.0	\$ 575.0	\$616.7	\$ 579.3
31/4% Debentures, excluding unamortized discount	\$225.0	\$ 225.0	\$231.4	\$ 225.6

The fair values of our Term B Loans and 6.625% Senior Notes were estimated based on the average bid and ask price as determined using published rates. The fair values of our 3½% Notes and 3¼% Debentures were estimated based on the quoted market prices determined using the closing share price of our common stock.

Cash Balances

Certain of our outstanding cash balances are invested overnight with high credit quality financial institutions. We do not hold direct investments in auction rate securities, collateralized debt obligations, structured investment vehicles or mortgage-backed securities. We do not have significant exposure to changing interest rates on invested cash at March 31, 2011. As a result, the interest rate market risk implicit in these investments at March 31, 2011, if any, is low.

Item 4. Controls and Procedures.

We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report pursuant to Rule 13a-15 of the Securities Exchange Act of 1934 (the Exchange Act). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us (including our consolidated subsidiaries) in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported on a timely basis.

There has been no change in our internal control over financial reporting during the three months ended March 31, 2011 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

39

Cash Balances 80

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

We are, from time to time, subject to claims and suits arising in the ordinary course of business, including claims for damages for personal injuries, medical malpractice, breach of contracts, wrongful restriction of or interference with physicians—staff privileges and employment related claims. In certain of these actions, plaintiffs request payment for damages, including punitive damages that may not be covered by insurance. We are currently not a party to any pending or threatened proceeding, which, in management—s opinion, would have a material adverse effect on our business, financial condition or results of operations.

In May 2009, our hospital in Andalusia, Alabama (Andalusia Regional Hospital) produced documents responsive to a request received from the U.S. Attorney s Office for the Western District of New York regarding an investigation they are conducting with respect to the billing of kyphoplasty procedures. Kyphoplasty is a surgical spine procedure that returns a compromised vertebra (either from trauma or osteoporotic disease process) to its previous height, reducing or eliminating severe pain. It has been reported that other unaffiliated hospitals and hospital operators in multiple states have received similar requests for information. We believe that this investigation is related to the May 22, 2008 qui tam settlement between the same U.S. Attorney s Office and the manufacturer and distributor of the product used in performing the kyphoplasty procedure.

Based on a review of the number of the kyphoplasty procedures performed at all of our other hospitals, as part of our effort to cooperate with the U.S. Attorney s Office, by letter dated January 20, 2010 we identified to the U.S. Attorney s Office four additional facilities at which the number of inpatient kyphoplasty procedures approximated those performed at Andalusia Regional Hospital. We have completed our review of the relevant medical records and we are continuing to cooperate with the government s investigation.

Item 1A. Risk Factors.

There have been no material changes in our risk factors from those disclosed in our 2010 Annual Report on Form 10-K

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In August 2009, our Board of Directors authorized the repurchase of up to \$100.0 million of outstanding shares of our common stock either in the open market or through privately negotiated transactions, subject to market conditions, regulatory constraints and other factors (the 2009 Repurchase Plan). The 2009 Repurchase Plan expired in February 2011. In connection with the 2009 Repurchase Plan, we repurchased approximately 0.2 million shares for an aggregate purchase price, including commissions, of \$5.2 million at an average purchase price of \$32.84 per share for the three months ended March 31, 2010. There were no repurchases made in accordance with the 2009 Repurchase Plan during the three months ended March 31, 2011. We have designated the shares repurchased in accordance with the 2009 Repurchase Plan as treasury stock.

In September 2010, our Board of Directors authorized the repurchase of up to an additional \$150.0 million of outstanding shares of our common stock either in open market purchases, privately negotiated transactions,

accelerated share repurchase programs or other transactions (the 2010 Repurchase Plan). The 2010 Repurchase Plan expires in March 2012. We are not obligated to repurchase any specific number of shares under the 2010 Repurchase Plan. There were no repurchases made in accordance with the 2010 Repurchase Plan during the three months ended March 31, 2011.

Additionally, we redeem shares from employees for minimum statutory tax withholding purposes upon vesting of certain stock awards granted pursuant to our Amended and Restated 1998 Long-Term Incentive Plan (LTIP) and Amended and Restated Management Stock Purchase Plan (MSPP). We redeemed approximately 0.1 million shares of certain vested LTIP and MSPP shares during each of the three months ended March 31, 2011 and 2010 for an aggregate price of \$5.5 million and \$3.8 million, respectively. We have designated these shares as treasury stock.

40

TABLE OF CONTENTS

The following table summarizes our share repurchase activity by month for the three months ended March 31, 2011:

Period	Total Number of Shares Purchased ^(a)	Weighted Average Price Paid per Share	Total Number of Shares Purchased as Part of a Publicly Announced	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
			Program	(In millions)
January 1, 2011 to January 31, 2011	4,332	\$ 35.65	C	\$ 103.6
February 1, 2011 to February 28, 2011	139,847	\$ 38.18		\$ 103.6
March 1, 2011 to March 31, 2011		\$		\$ 103.6
Total	144,179	\$ 38.11		\$ 103.6

⁽a) Consists of shares redeemed for tax withholding purposes upon vesting of certain previously granted stock awards under our various stockholder-approved stock-based compensation plans.

41

Item 6. Exhibits

Exhibit Number	Description of Exhibits
3.1	Amended and Restated Certificate of Incorporation (incorporated by reference from exhibits to the Registration Statement on Form S-8 filed by LifePoint Hospitals, Inc. on April 19, 2005, File No. 333-124151).
3.2	Fourth Amended and Restated By-Laws of LifePoint Hospitals, Inc. (incorporated by reference from exhibits to the LifePoint Hospitals, Inc. Current Report on Form 8-K dated December 15, 2010, File No. 000-51251).
10.1	Amendment to the LifePoint Hospitals Deferred Compensation Plan, dated December 22, 2010 (filed herewith).*
10.2	Amendment to the LifePoint Hospitals Deferred Compensation Plan, dated March 14, 2011(filed herewith).*
31.1	Certification of the Chief Executive Officer of LifePoint Hospitals, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of the Chief Financial Officer of LifePoint Hospitals, Inc. pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.1	Certification of the Chief Executive Officer of LifePoint Hospitals, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of the Chief Financial Officer of LifePoint Hospitals, Inc. pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.INS	XBRL Instance Document**
101.SCH	XBRL Taxonomy Extension Schema Document**
101.CAL	XBRL Taxonomy Calculation Linkbase Document**
101.DEF	XBRL Taxonomy Definition Linkbase Document**
101.LAB	XBRL Taxonomy Label Linkbase Document**
101.PRE	XBRL Taxonomy Presentation Linkbase Document**

^{*} Management Compensation Plan or Arrangement

42

Item 6. Exhibits 84

^{**} Furnished electronically herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LifePoint Hospitals, Inc. By:

/s/ Michael S. Coggin Michael S. Coggin Senior Vice President and Chief Accounting Officer (Principal Accounting Officer)

Date: April 29, 2011

43

SIGNATURES 85

TABLE OF CONTENTS

Exhibit Number	Description of Exhibits
3.1	Amended and Restated Certificate of Incorporation (incorporated by reference from exhibits to the Registration Statement on Form S-8 filed by LifePoint Hospitals, Inc. on April 19, 2005, File No. 333-124151).
3.2	Fourth Amended and Restated By-Laws of LifePoint Hospitals, Inc. (incorporated by reference from exhibits to the LifePoint Hospitals, Inc. Current Report on Form 8-K dated December 15, 2010, File No. 000-51251).
10.1	Amendment to the LifePoint Hospitals Deferred Compensation Plan, dated December 22, 2010 (filed herewith).*
10.2	Amendment to the LifePoint Hospitals Deferred Compensation Plan, dated March 14, 2011 (filed herewith).*
31.1	Certification of the Chief Executive Officer of LifePoint Hospitals, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of the Chief Financial Officer of LifePoint Hospitals, Inc. pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32.1	Certification of the Chief Executive Officer of LifePoint Hospitals, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of the Chief Financial Officer of LifePoint Hospitals, Inc. pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
101.INS	XBRL Instance Document**
101.SCH	XBRL Taxonomy Extension Schema Document**
101.CAL	XBRL Taxonomy Calculation Linkbase Document**
101.DEF	XBRL Taxonomy Definition Linkbase Document**
101.LAB	XBRL Taxonomy Label Linkbase Document**
101.PRE	XBRL Taxonomy Presentation Linkbase Document**

^{*} Management Compensation Plan or Arrangement

SIGNATURES 86

^{**} Furnished electronically herewith